Assessing causal effects in the presence of treatment switching through
  principal stratification by Mattei, Alessandra et al.
Assessing causal effects in the presence of
treatment switching through principal
stratification
Alessandra Mattei∗, Peng Ding†, and Fabrizia Mealli∗
∗University of Florence and †UC Berkeley
Abstract
Clinical trials focusing on survival outcomes often allow patients in the control
arm to switch to the treatment arm if their physical conditions are worse than
certain tolerance levels. The Intention-To-Treat analysis provides valid causal
estimates of the effect of assignment, but it does not measure the effect of the
actual receipt of the treatment and ignores the information of treatment switch-
ing. Other existing methods propose to reconstruct the outcome a unit would
have had if s/he had not switched under strong assumptions. We propose to re-
define the problem of treatment switching using principal stratification focusing
on principal causal effects for patients belonging to subpopulations defined by
the switching behavior under control. We use a Bayesian approach to inference
taking into account that (i) switching happens in continuous time generating
infinitely many principal strata; (ii) switching time is not defined for units who
never switch in a particular experiment; and (iii) survival time and switching
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time are subject to censoring. We illustrate our framework using a synthetic
dataset based on the Concorde study, a randomized controlled trial aimed to as-
sess causal effects on time-to-disease progression or death of immediate versus
deferred treatment with zidovudine among patients with asymptomatic HIV
infection.
Keywords: Causal inference; Censoring; Potential outcomes; Survival
1. Introduction
Treatment switching commonly occurs in clinical trials designed to assess the effect
of a treatment on the incidence of a disease. There are various types of treatment
switching. For example, during the follow-up period, the treatment may cause un-
wanted side effects for some patients preventing them from continuing taking the
treatment. In other cases, a sudden worsening of the disease for some weaker units
forces physicians to allow them to switch to the treatment arm or take a non-trial
treatment. Here we focus on clinical trials where patients in the treatment arm never
switch to the control arm, but patients in the control arm can switch to the treat-
ment arm if their physical conditions are worse than certain tolerance levels. This
type of switching often happens in clinical trials focusing on survival outcomes for
patients suffering from AIDS-related illnesses or particularly painful cancers in ad-
vanced stages (e.g., Robins and Tsiatis 1991; Robins 1994; White et al. 1997, 1999;
Zeng et al. 2011; Chen et al. 2013). In these trials, the control arm consists of a
placebo, no treatment, or delayed treatment.
As a motivating example, we consider a randomized clinical trial aimed to assess
causal effects of immediate versus deferred treatment with an antiretroviral med-
ication (zidovudine) on time-to-disease progression or death among symptom-free
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individuals infected with HIV. According to the trial protocol, patients assigned to
the control group should not receive the active treatment until they progressed to
AIDS-related complex (ARC) or AIDS. However, physicians may judge unethical to
keep patients in the control arm if their physical conditions worsen considerably, such
as, e.g., if they experience persistently low CD4 cell counts even before the onset of
ARC or AIDS.
Intention-To-Treat (ITT) analysis is often used in studies with such complications.
It compares groups formed by randomization regardless of the treatment actually
received, entirely ignoring the information of treatment switching in the control group.
This approach is valid for measuring the effect of assignment, but it does not estimate
the effect of the actual receipt of the treatment. The latter is called the “biological
effect”, which is usually the causal estimand of interest. See Greenland et al. (2008)
for a review. In the motivating study, an ITT analysis compares outcomes by the
assignment to immediate versus deferred treatment with zidovudine, ignoring whether
control patients actually receive the control treatment for the entire follow-up period
(or, according to the protocol, up to the onset of ARC or AIDS). If focus is on assessing
the effects of the treatment itself, that is, of receiving zidovudine immediately versus
subsequently, after the onset of ARC or AIDS, we cannot ignore treatment switching.
Unfortunately we cannot adjust treatment comparisons for treatment switch-
ing by simply conditioning on its observed value, because treatment switching is
a post-assignment intermediate confounded variable, and thus it is endogenous (non-
ignorable). Imagine that immediate treatment with zidovudine increases every in-
dividual’s survival but weaker patients who are most at risk of death would switch
very early if assigned to control. A naive analysis that compares observed immediate
versus observed deferred treatment with zidovudine may - unfairly - conclude that
the first has no or little effect on survival.
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In the causal inference literature the problem of adjusting treatment comparisons
for confounded post-treatment variables is usually addressed using principal stratifi-
cation (Frangakis and Rubin 2002). Following this literature, we propose to re-define
the problem of treatment switching using principal stratification. We introduce new
causal estimands, principal causal effects for patients belonging to subpopulations
defined by the switching behavior under control. The key insight underlying our ap-
proach is that treatment switching can be viewed as a general form of noncompliance.
Principal stratification plays an important role in the analysis of randomized studies
with all-or-none noncompliance, where it classifies units into groups defined by the
compliance status and focus is on causal effects for compliers (Angrist et al. 1996). In
clinical trials with treatment switching, classifying units into subpopulations defined
by the switching behavior is an extension of grouping units based on the compliance
status. To the best of our knowledge, no published studies used principal stratification
to deal with the problem of treatment switching.
Principal stratification focuses on principal causal effects, which are local causal
effects for patients who are homogeneous with respect to the switching behavior.
Therefore, principal causal effects provide information on treatment effect hetero-
geneity with respect to the switching behavior. Some principal causal effects are
more interesting than others, in as much the same way that causal effects for compli-
ers are more interesting than those for never-takers and always-takers. In our case,
the principal stratum of non-switchers will be of particular interest. Non-switchers
are patients who would never switch to the active treatment if assigned to the control
treatment. They are a specific type of compliers, because they take the treatment
and control according to the protocol, and thus can provide evidence on the causal
effect of treatment versus control.
With treatment switching, causal inference is extremely challenging. First, the
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switching of the units under control either never happens or happens at a continuous
time. Second, the assumptions such as the exclusion restrictions, typically invoked
in the noncompliance setting, are untenable in studies with treatment switching. We
will discuss these issues in detail in Section 2. We deal with inferential issues using a
flexible model-based Bayesian approach, which allows us to take into account that (i)
switching happens in continuous time generating a continuum of principal strata; (ii)
switching time is not defined for units who never switch in a particular experiment;
and (iii) survival time and switching time are subject to censoring. We illustrate
our framework using a synthetic dataset based on the Concorde study, a random-
ized controlled trial aimed to assess causal effects on time-to-disease progression or
death of immediate versus deferred treatment with zidovudine among patients with
asymptomatic HIV infection.
2. Treatment switching with censoring
2.1. Potential outcomes
Consider a randomized controlled clinical trial with n patients suffering from AIDS-
related illnesses or particularly painful cancers in advanced stages, where n1 of them
are assigned to the treatment and n0 of them are assigned to the control. The objective
is to assess causal effects of the treatment on a time-to-event outcome, Y (e.g., survival
time or time to disease progression). We use potential outcomes to define causal effects
(Neyman 1923; Rubin 1974), and make the stable unit treatment value assumption
(Rubin 1980). Let Yi(z) ≥ 0 and Ci(z) ≥ 0 be the potential survival time and
censoring time for unit i under treatment assignment z (z = 0, 1). The survival
time is subject to censoring. The trial starts and ends at specific calendar times,
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which determine a fixed duration of the study, c. Therefore, the censoring time
depends on units’ entry, which is staggered over time. Thus, Ci(z) ≤ c represents the
duration till the end of the study for unit i given treatment assignment z. We assume
Ci(0) = Ci(1) = Ci for all i = 1 . . . , n.
As the trial goes on, it is unethical to keep the units staying in the control arm
if their physical conditions are worse than certain tolerance levels. Therefore, some
units might switch to the treatment even if they had been assigned to the control.
Some trials permit patients in the treatment arm to switch to control if, e.g., they
experience adverse reaction to the treatment. Here we focus on one-sided switching,
i.e., only patients in the control arm can switch to the treatment. Let Si(z) be the
potential switching status of unit i under treatment assignment z, the value of which
needs careful discussion. First, in the presence of one-sided switching behaviour, unit
i’s switching status is Si(0), the potential switching status under control. Because
units in the treatment arm cannot switch, we define Si(1) = S for i = 1, . . . , n, where
the symbol “S” is a non-real value. Second, a unit i may not switch from the control
to treatment no matter how long the follow-up is, implying Si(0) = S. Third, a
unit i can switch to the treatment arm only before her/his survival time, implying a
natural constraint Si(0) ≤ Yi(0). The natural constraint implies that for patients who
would die under the control treatment without switching to the active treatment, the
switching time, Si(0), is censored by death, with the censoring event (death/survival
time) defined by the potential outcome under control for the main endpoint, Yi(0).
For this type of units the switching time is not only not observed but also undefined,
and thus Si(0) = S. Fourth, the switching time is also subject to censoring.
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2.2. Causal estimands
Causal effects are comparisons of the treatment and control potential outcomes for a
common set of units. The average causal effect of treatment assignment is often of
interest:
ACE = E [Yi(1)]− E [Yi(0)] . (1)
When assessing whether the treatment can prolong survival of patients, we are also
interested in the distributional causal effect:
DCE(y) = P {Yi(1) > y} − P {Yi(0) > y} , (y ∈ R+). (2)
Ju and Geng (2010) noted that ACE =
∫ +∞
0
DCE(y)dy. Although the average causal
effect in (1) and the distributional effect in (2) measure well-defined intention-to-
treat causal effects, they ignore the information on treatment switching in the control
group.
We adopt principal stratification (Frangakis and Rubin 2002) to define causal
estimands adjusted for the treatment switching behavior. We classify units into latent
groups, named principal strata, defined by the potential outcome of the treatment
switching status under assignment z = 0, Si(0). Frangakis and Rubin (2002) pointed
out that Si(0) is a pretreatment covariate unaffected by the treatment assignment.
The variable S(0) is semi-continuous, because switching either does not happen or
happens in continuous time. Therefore, the basic principal stratification with respect
to the treatment switching status consists of a continuum of principal strata. Each
principal stratum comprises units with the same value of the switching status: {i :
Si(0) = s}, s ∈ {S} ∪ R+. Throughout the paper we refer to units with Si(0) = S as
non-switchers, and to units with a positive real value Si(0) = s as switchers. Switchers
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belong to ∪s∈R+{i : Si(0) = s}, the union of the basic principal strata {i : Si(0) = s},
s ∈ R+. Causal effects within principal strata are called principal causal effects. We
focus on principal average causal effects:
ACE(s) = E [Yi(1) | Si(0) = s]− E [Yi(0) | Si(0) = s] (3)
s ∈ {S} ∪ R+, and principal distributional causal effects:
DCE(y | s) = P {Yi(1) > y | Si(0) = s} − P {Yi(0) > y | Si(0) = s} , (4)
y ∈ R+, s ∈ {S} ∪ R+.
Because non-switchers would not switch to treatment if assigned to control, for
them treatment received coincides with treatment assigned. Thus, principal causal
effects for non-switchers are attributable to treatment received, that is, the principal
causal effects ACE(S) and DCE(y | S) can be interpreted as effects of the treatment.
Principal causal effects for non-switchers are analogous to causal effects for compliers
in randomized experiments with non-compliance, i.e., ACE(S) is analogous to the
compliers average causal effect (see Section 4 for an in-depth discussion about the
connection between the switching problem and the noncompliance literature).
The estimands ACE(y | s) and DCE(y | s) for s ∈ R+ measure the average causal
effect and the distributional causal effect for units who would switch to the treatment
arm at time s had they been assigned to the control arm. For y ∈ R+ and s ∈ R+,
DCE(y | s) defines a two-dimensional surface on R+ × R+. The natural constraint
Si(0) ≤ Yi(0) implies that P {Yi(0) > y | Si(0) = s} = 1 for y ≤ s, and thus the prin-
cipal distributional causal effect reduces to DCE(y | s) = P {Yi(1) > y | Si(0) = s}−1
for y ≤ s. If we further assume monotonicity Yi(1) ≥ Yi(0), then Yi(1) ≥ Si(0) and
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Figure 1: Examples of principal distributional causal effects under monotonicity (c =
3)
the principal distributional causal effect reduces to DCE(y | s) = 0 for y ≤ s. In this
case, for a fixed value of Si(0) = s, s ∈ R+, the principal distributional causal effect
curve is non-negative within the interval [s, c] as depicted by Figure 1.
Monotonicity states that the treatment does prolong survival compared to the
control. It cannot be directly validated and can be suspicious. Without monotonicity,
the principal distributional causal effect DCE(y | s) is negative (or at most zero)
by construction for y ≤ s. A structural negative effect may lead to a misleading
interpretation of the effectiveness of the treatment. Therefore, it is sensible to consider
the conditional principal distributional causal effect: For y, s ∈ R+,
cDCE(y | s) (5)
= P {Yi(1) > y | Yi(1) ≥ Si(0), Si(0) = s} − P {Yi(0) > y | Yi(1) ≥ Si(0), Si(0) = s}
= P {Yi(1) > y | Yi(1) ≥ s, Si(0) = s} − P {Yi(0) > y | Yi(1) ≥ s, Si(0) = s} .
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For y ≤ s, cDCE(y | s) = 1 − 1 = 0. The estimand cDCE(y | s), s ∈ R+ measures
the distributional causal effect on the residual survival time from the switching time
for units who would switch to the treatment arm at time s had they been assigned
to control.
The principal causal effects in (3)–(5) classify the units according to the detailed
value of Si(0), and thus they are basic principal causal effects (Frangakis and Rubin
2002). Furthermore, we can define coarsened principal causal effects
ACE(A) = E [Yi(1) | Si(0) ∈ A]− E [Yi(0) | Si(0) ∈ A] , (6)
DCE(y | A) = P {Yi(1) > y | Si(0) ∈ A} − P {Yi(0) > y | Si(0) ∈ A} , (7)
cDCE(y | A) = P {Yi(1) > y | Yi(1) ≥ Si(0), Si(0) ∈ A} (8)
P {Yi(0) > y | Yi(1) ≥ Si(0), Si(0) ∈ A} ,
where A is a subset of R+. The simplest example is A = R+, which implies that the
causal effects in Equations (6), (7) and (8) are the causal effects for the coarsened
stratum of all switchers. The causal effects in Equations (6), (7) and (8) are the
causal effects for units who would switch earlier and later than time s if assigned to
control for A = [0, s] and for A = (s,+∞), respectively. Explicit formulae for these
examples are shown in Web Supplementary Material.
In general, we can discretize the switching time into several disjoint intervals
R+ = A1 ∪ · · · ∪ AK , and define ACE(Ak), DCE(y | Ak) and cDCE(y | Ak) for
k = 1, . . . , K. When K = 2, A1 = [0, s] and A2 = (s,+∞), these coarsened principal
causal effects reduce to causal effects for units who would switch earlier and later
than time s for k = 1 and for k = 2, respectively. However, units switching at
different times have different characteristics, and the basic principal causal effects
conditioning on the potential switching time give detailed information on treatment
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effect heterogeneity.
2.3. Observed data
The potential outcome for the switching status under control, Si(0), and the potential
outcomes for survival, Yi(0) and Yi(1), are well defined and a-priori observable for
all units, in the sense that they could be observed if the units were assigned to the
corresponding treatment level (at least in absence of censoring). A-posteriori, once the
treatment has been assigned, for each unit only the potential outcome corresponding
to the treatment actually assigned is observed; the other potential outcome is missing.
For unit i, let Zi denote the treatment assignment: Zi = 1 for the treatment
and Zi = 0 for the control. Without censoring, let Y
obs
i = ZiYi(1) + (1 − Zi)Yi(0)
and Sobsi = ZiS + (1 − Zi)Si(0) denote the survival time and switching time under
the actual treatment assignment. Let Y˜ obsi = min{Y obsi , Ci} denote the censored
survival time. For units assigned to treatment, we set the switching time to be
S˜obsi = S
obs
i = Si(1) = S; for units assigned to control, we observe the censored
switching time:
S˜obsi =S
obs
i I{Sobsi ∈ R+}I{Sobsi ≤ Ci}+ Ci
[
I{Sobsi ∈ R+}I{Sobsi > Ci}+ I{Sobsi = S}
]
=Si(0)I{Si(0)∈R+}I{Si(0)≤Ci}+Ci
[
I{Si(0)∈R+}I{Si(0)>Ci}+ I{Si(0)=S}
]
.
In general, we do not observe the principal stratum of a patient, for different
reasons in the treatment and control arms. In the treatment arm, we observe no
treatment switching, and the potential outcome Si(0) is missing. Therefore, a unit
in the treatment arm may belong to any principal stratum defined by Si(0), and the
treatment group results in an infinite mixture of principal strata. In the control arm,
both the survival time and switching time are subject to censoring. We have the
11
following cases.
(a) The unit dies at time Y obsi ≤ Ci and does not switch to the treatment arm, i.e.,
S˜obsi = Ci and Y˜
obs
i = Y
obs
i . The natural constraint implies that S
obs
i = Si(0) =
S. This unit is a non-switcher belonging to stratum {i : Si(0) = S}.
(b) The unit switches to the treatment arm at time Sobsi and dies at time Y
obs
i with
Sobsi < Y
obs
i ≤ Ci, i.e., S˜obsi = Sobsi = Si(0) = s ∈ R+, and Y˜ obsi = Y obsi = Yi(0).
This unit is a switcher belonging to stratum {i : Si(0) = s}.
(c) The unit switches to the treatment arm at time Sobsi ≤ Ci but does not die before
the end of the study, i.e., S˜obsi = S
obs
i = Si(0) = s ∈ R+, and Y˜ obsi = Ci < Y obsi .
This unit is a switcher belonging to stratum {i : Si(0) = s}.
(d) The unit neither switches to the treatment arm nor dies before the end of the
study (with Sobsi ∈ {S} ∪ (Ci,+∞) and Y obsi > Ci), i.e., S˜obsi = Y˜ obsi = Ci.
This unit may be a switcher with Ci < S
obs
i = Si(0) < Y
obs
i = Yi(0), or a
non-switcher with Sobsi = Si(0) = S and Y obsi = Yi(0) > Ci. This unit belongs
to either stratum {i : Si(0) = S} or the union of strata ∪s>Ci{i : Si(0) = s}.
Cases (a)–(c) have clear values of the switching time and survival time, at least
hypothetically, so that we directly observe the principal strata for these types of units.
Case (d) is less clear due to censoring: the principal stratum membership for units
with S˜obsi = Y˜
obs
i = Ci is missing. Table 1 shows the data pattern and latent principal
strata associated with each observed group.
2.4. Identification issues under randomization
Let Xi be a K-dimensional vector of pre-treatment variables. We consider a com-
pletely randomized trial where the following assumption holds by design:
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Table 1: Observed data pattern and possible latent principal strata
Zi S˜
obs
i Y˜
obs
i Principal strata Principal stratum label
0 Ci Y
obs
i ∈ [0, Ci] {i : Si(0) = S} Non-switchers
0 Sobsi ≤ Ci Y obsi ∈ [Sobsi , Ci] {i : Si(0) = Sobsi } Switchers at time
(Sobsi ∈ R+) Sobsi ∈ R+
0 Sobsi ≤ Ci Ci {i : Si(0) = Sobsi } Switchers at time
(Sobsi ∈ R+) Sobsi ∈ R+
0 Ci Ci
{
i : Si(0) = S
}
or Non-switchers or
{i : Si(0) = s ∈ (Ci,+∞)} Switchers at
some time s > Ci
1 S Y obsi ∈ [0, Ci]
{
i : Si(0) = S
}
or Non-switchers or
{Si(0) ∈ R+} Switchers
1 S Ci
{
i : Si(0) = S
}
or Non-switchers or
{Si(0) ∈ R+} Switchers
Assumption 1 (Completely Randomized Experiment).
P {Zi | Si(0), Yi(0), Yi(1), Ci, Xi} = P {Zi} .
We assume that the censoring mechanism is independent of both the survival time
and the switching time.
Assumption 2 (Ignorability of the Censoring Mechanism).
P {Ci | Si(0), Yi(0), Yi(1), Xi} = P {Ci} .
This assumption implies that the distribution of the censoring times contains no
information about the distributions of the potential survival and switching time.
We can also extend the discussion under unconfoundedness of the treatment as-
signment, P {Zi | Si(0), Yi(0), Yi(1), Ci, Xi} = P {Zi | Xi} , and ignorability of the
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censoring mechanism conditional on observed pretreatment variablesXi, P {Ci | Si(0), Yi(0),
Yi(1), Xi} = P {Ci | Xi}. The following discussion would be applicable within cells
defined by Xi.
Randomization helps inference. It implies that the distribution of the switching
behavior, Si(0), is the same in both treatment arms. Moreover it allows us to express
the distributional causal effects of the treatment assignment on the survival time in
(2) by the distribution of the observed data:
DCE(y) = P
{
Y obsi > y | Zi = 1
}− P {Y obsi > y | Zi = 0} .
Under ignorability of the censoring mechanism, we can estimate the survival func-
tions P
{
Y obsi > y | Zi = z
}
for y ∈ [0, c] by the empirical survival functions under
treatment z, z = 0, 1. Without imposing further assumptions, the data provide no
information about the survival functions for y ∈ (c,+∞). Therefore, the identifica-
tion of the average causal effect must rely on further (parametric) assumptions on Y ,
because ACE =
∫ c
0
DCE(y)dy+
∫ +∞
c
DCE(y)dy depends on the distributional causal
effect within both the intervals [0, c] and (c,+∞).
It is even more challenging to identify the average principal causal effects and
principal distributional causal effects. For instance, the distributional effect for the
non-switchers, DCE(y | S), is, in general, different from the prima facie distributional
effect,
FDCE(y | S) = P {Y obsi > y | Zi = 1}− P {Y obsi > y | Zi = 0, Sobsi = S} ,
the naive comparison between the units that do not switch under treatment and con-
trol. The prima facie effect would be different from DCE(y | S), even if there were no
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censored cases. Without censoring, randomization implies P
{
Yi(0) > y | Si(0) = S
}
=
P
{
Y obsi > y | Zi = 0, Sobsi = S
}
, and if we assume that switchers are weaker people
than non-switchers, then FDCE(y | S) is a lower bound for DCE(y | S). More pre-
cisely, if P
{
Yi(1) > y | Si(0) = S
} ≥ P {Yi(1) > y | Si(0) ∈ R+}, then
P
{
Y obsi > y | Zi = 1
}
= P
{
Yi(1) > y |Si(0) = S
}
P
{
Si(0) = S
}
+P {Yi(1) > y |Si(0) ∈ R+}P {Si(0) ∈ R+}
≤ P {Yi(1) > y | Si(0) = S} ,
which implies that FDCE(y | S) ≤ DCE(y | S).
3. Bayesian Inference
In our study, inference on principal causal effects is particularly challenging due to
the nature of the intermediate variable, which is a time-to-event outcome subject to
censoring. Because we generally do not observe the principal stratum membership,
we have to deal with a large amount of missing data, and the principal causal effects
of interest are, in general, either not or only partially identified. We propose to face
the identification and estimation issues using a flexible Bayesian parametric approach,
which is often preferred in principal stratification analysis where inference involves
techniques for incomplete data (e.g., Mattei and Mealli 2007; Jin and Rubin 2008,
2009; Zigler and Belin 2012; Schwartz et al. 2011; Kim et al. 2017). Conceptually,
the Bayesian approach does not require full identification (Lindley 1972): Bayesian
inference is based on the posterior distribution of the parameters of interest, which
is derived by updating a prior distribution via a likelihood, irrespective of whether
the parameters are fully or partially identified, and it is always proper if the prior
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distribution is proper (e.g., Gustafson 2010). Nevertheless, in finite sample, posterior
distributions of partially identified parameters may be weak identifiabible in the sense
that they may have substantial region of flatness (e.g., Imbens and Rubin 1997;
Schwartz et al. 2011). Another appealing feature of the Bayesian approach is that it
allows us to deal with all complications – missing data, truncation by death, censoring
– simultaneously in a natural way. Moreover, in Bayesian analysis inferences are
directly interpretable in probabilistic terms.
We now sketch our Bayesian principal stratification approach, referring to Web
Supplementary material for a detailed description. In our setting each unit is as-
sociated with six quantities: Zi, Ci, Si(0), Yi(0), Yi(1), and Xi. Bayesian inference
considers the observed values of these quantities to be realizations of random variables
and the unobserved values to be unobserved random variables (Rubin 1978). Under
randomization (Assumption 1), ignorability of the censoring mechanism (Assumption
2), and exchangeability, Bayesian inference for principal causal effects involves two
sets of models: one for the principal strata defined by the switching status, Si(0),
given the covariates, Xi, and the other for the distribution of potential survival times
Yi(0) and Yi(1) conditional on the switching status, Si(0), and covariates, Xi. Both
distributions are parametrized so that conditional on a general parameter, denoted
by θ, with prior distribution P (θ), the model has an independent and identical dis-
tribution (i.i.d.) structure.
3.1. Parametric assumptions
We adopt flexible parametric models for the switching status and the survival times.
We use the Weibull distribution to model the potential switching time and survival
times. The Weibull model has appealing features: its hazard and survival functions
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have a simple form, and it is flexible and easily to interpret. We can similarly consider
alternative survival models, such as Burr models (e.g., Mealli and Pudney 2003) or
Bayesian semi- or non-parametric models (e.g. Ibrahim et al. 2001; Schwartz et al.
2011; Kim et al. 2017). The Weibull model has two positive parameters α and ξ. The
parameter α allows for different shapes of the hazard function. The hazard function
monotonically decreases if α < 1, is constant if α = 1, and monotonically increases if
α > 1. We write the Weibull model in terms of the parameterization (α, log(ξ)).
First, we model Si(0). We assume that the binary indicator I{Si(0) = S} follows
a Bernoulli distribution with probability of success
pi(xi) =
exp(η0 + x
′
iη)
1 + exp(η0 + x′iη)
, (η0,η) ∈ RK+1.
Given that Si(0) does not take value S, we assume that it follows a Weibull distribution
Si(0) | Si(0) ∈ R+, Xi ∼Weibull (αS, βS +X ′iηS), αS > 0, βS ∈ R, ηS ∈ RK .
Second, we model Yi(0) | Si(0), Xi. We assume that Yi(0) | Si(0) = S, Xi follows
a Weibull distribution with parameters
(
α¯Y , β¯Y +X
′
iη¯Y
)
, α¯Y > 0, β¯Y ∈ R and η¯Y ∈
RK .
Given Si(0) ∈ R+, we model Yi(0) as a location shifted Weibull distribution:
Yi(0) | Si(0), Xi ∼ Si(0) + Weibull (αY , βY + λ0 logSi(0) +X ′iηY ), αY > 0, βY , λ0 ∈
R, ηY ∈ RK . This location shift parametrization reflects the constraint Yi(0) ≥ Si(0)
for switchers.
Third, we model Yi(1) | Si(0), Yi(0), Xi. We assume that Yi(1) for non-switchers
follows a location shifted Weibull distribution: Yi(1) | Si(0) = S, Yi(0), Xi ∼ κYi(0) +
Weibull
(
ν¯Y , γ¯Y +X
′
iζ¯
)
, κ ∈ [0, 1], ν¯Y > 0, γ¯Y ∈ R, ζ¯ ∈ RK .
Given Si(0) ∈ R+, we model Yi(1) as a location shifted Weibull distribution:
Yi(1) | Si(0), Yi(0), Xi ∼ κYi(0) + Weibull (νY , γY + λ logSi(0) +X ′iζ), κ ∈ [0, 1],
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νY > 0, γY , λ1 ∈ R, ζ ∈ RK . In web Supplementary material, we explicitly show the
probability density functions, the survivor functions, and the hazard functions corre-
sponding to these model assumptions. Therefore, the entire parameter vector is θ =[
(η0,η), (αS, βS,ηS),
(
α¯Y , β¯Y , η¯Y
)
, (αY , βY , λ0,ηY ),
(
ν¯Y , γ¯Y , ζ¯Y
)
, (νY , γY , λ1, ζY ),
κ
]
.
3.2. Identification of some model parameters
The parameters λ1 and κ deserve some discussion. The parameter κ characterizes the
dependence between Yi(1) and Yi(0) given {Si(0), Xi}. The observed data provide
little information on κ because we can observe only one of the potential survival
time for each unit. We can view κ as a sensitivity parameter: when κ = 0, the
potential survival times, Yi(1) and Yi(0) are conditionally independent; when κ = 1,
monotonicity Yi(1) ≥ Yi(0) holds. In practice, we suggest conducting sensitivity
analysis by varying κ within the range [0, 1].
The parameter λ1 describes the association between Yi(1) and Si(0) given Yi(0) for
switchers. Because Si(0) is never observed for treated units, the observed data provide
no direct information about the partial association between Yi(1) and Si(0) given
Yi(0). We propose to deal with this identifiability issue by introducing parametric
assumptions that allow us to borrow some information on λ1 from the observed data.
We impose prior equality of the association parameters λ0 and λ1: λ ≡ λ0 = λ1, so
that a common parameter, λ, is used to describe the association between Yi(1) and
Si(0) given Yi(0) and between Yi(0) and Si(0). Because Yi(0) and Si(0) are jointly
observed for some control units, we have some information on the association between
Yi(0) and Si(0), and thus on the parameter λ.
It is worth noting that some values of the parameters (λ, κ) correspond to invoking
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specific structural assumptions. For instance, under our model specification, if κ = 1
and λ < 0 then Yi(1) ≈ Yi(0) for each unit i with Si(0) ∈ R+ and Si(0) ≈ 0. In fact,
if κ = 1 and λ < 0, lim
s→0
GY (1)(y | s, y0, xi) = lim
s→0
P{Y (1)− y0 > y | Si(0) = s, Yi(0) =
y0, Xi = xi} = 0 for each y, y0 ∈ R+, and thus Yi(1) ≈ Yi(0) with probability one.
This is a type of “exclusion restriction,” which assumes that the assignment has no
or little effect on the survival outcome for switchers if they would immediately switch
to the treatment arm had they assigned to the control arm.
If ν¯Y = νY , γ¯Y = γY , λ = 0, and κ = 0, then the switching status is independent
of the survival time under treatment given covariates: Yi(1) ⊥ Si(0) | Xi. This as-
sumption, which implies that the distribution of Yi(1) | Si(0), Yi(0), Xi is identifiable,
is a form of principal ignorability (e.g., Jo and Stuart 2009; Ding and Lu 2017; Feller
et al. 2017).
Parameters (λ, κ) are generally not nonparametrically identified. Nevertheless,
(λ, κ) enter the observed data likelihood, and thus enter the Bayesian posterior in-
ference. Therefore, they are at least partially identified and could be parametrically
identified depending on the modeling assumptions (Gustafson 2010). Information
on these parameters is implicitly embedded in the model for the joint potential
outcomes Yi(0) and Yi(1) conditional on {Si(0), Xi}. Such a model provides the
structure to recover the relationship between the observed and missing potential out-
comes. We factorize the joint conditional distribution of P{Yi(0), Yi(1) | Si(0), Xi}
into the product of P{Yi(0) | Si(0), Xi} and P{Yi(1) | Yi(0), Si(0), Xi}. The model for
P{Yi(0) | Si(0), Xi} characterizes the relationship between the survival outcome and
the switching status under control. The model for P{Yi(1) | Yi(0), Si(0), Xi} provides
the structure to recover the relationship among the potential survival outcomes and
the switching status under control. The data-augmentation algorithm (Tanner and
Wong 1987), briefly described later in Section 3.4 and detailed in Web Supplementary
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Material, further provides intuition about how the observed data and model speci-
fication together allow for drawing information on the missing potential outcomes,
and thus on the parameters (λ, κ). We draw the missing switching status for control
units from a distribution that depends on S˜obsi through the distribution of Y˜
obs
i . Then
we draw the missing switching status and the missing survival time under control for
treated units from a joint distribution that depends on the distribution of Y˜ obsi .
Given the possible sensitivity of the prior specifications for (λ, κ), we will conduct
various sensitivity analyses in the next section.
3.3. Priors and sensitivity parameters
We assume that the parameters are a priori independent. We propose to use Normal
prior distributions for the parameters of the logistic regression model for the mixing
probability, pi(Xi), Gamma prior distributions for the shape parameters of the Weibull
distributions and Normal prior distributions for the other parameters of the Weibull
distributions (See Web Supplementary Material for details).
We investigate the sensitivity of the results with respect to the prior specification
for λ using both more informative priors (e.g., Normal priors with a smaller variance)
as well as a less informative prior (e.g., a uniform prior distribution).
We use a Dirac delta prior for the sensitivity parameter κ concentrated at a pre-
fixed value κ0 ∈ [0, 1], which is essentially the same as fixing κ at κ0 a priori. We assess
the sensitivity of the conclusions to different assumptions on κ, by examining how
the posterior distributions of the causal estimands change with respect to different κ0
within the range [0, 1].
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3.4. Likelihood and posterior distributions
The observed-data likelihood has a complex form involving infinite mixtures, because
we do not observe the switching status under treatment and only partially observe the
survival time under control due to censoring. Therefore, it is extremely complicated
to infer the causal estimands of interest based on the observed-data likelihood directly.
We use the data augmentation algorithm: within each iteration, we first impute the
missing switching status and the missing survival time, and we then draw the model
parameters based on the complete-data posterior. The complete-data posterior is
easy to deal with because it does not involve any mixture distributions. We can
compute the causal estimands as byproducts within each iteration, and therefore we
can simulate their posterior distributions. See the Web Supplementary Material for
the likelihood, posterior, and more computational details.
4. Treatment switching methods: A review
In the causal inference literature, various methods have been proposed to evaluate
the effect of a treatment accounting for treatment switching.
To the best of our knowledge, all the existing methods generally focus on causal
effects for the whole population, which are defined under the assumption that there
exist, for each individual, the outcome that would have happened under assignment
to treatment and the outcome that would have happened under assignment to control
if that individual had not switched. Unfortunately, for switchers the outcome that
would have happened if they had not switched does not exist conceptually in the
data, it is an a-priori counterfactual (Frangakis and Rubin 2002). The data contain
no or little information on these a-priori counterfactual outcomes for switchers, and
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thus assumptions that allow one to extrapolate from the observed data information
on them are required.
It is worth noting that the problem of introducing assumptions that allow one
to extrapolate from the observed data information on quantities that do not exist in
the data for some units also arises in randomized experiments with non-compliance,
when focus is on causal effects for the whole population. In these experiments, the
Instrumental Variable (IV) assumptions (exogeneity of the instrument, existence of
an association between the instrument and the treatment, exclusion restrictions and
monotonicity) are sufficient to identity average causal effects for the sub-population
of compliers, but they are not sufficient to identify the average effect of the treat-
ment for the full population: in addition to the IV assumptions (with or without
monotonicity), we need to introduce additional assumptions that allow one to infer
the overall average effect, that is, assumptions on priori-conterfactual outcomes for
never-takers and always-takers. In the literature alternative sets of assumptions have
been considered including the rather strong assumption of identical treatment effect
for all units and the weaker homogeneity assumption of no additive effect modification
across levels of the instrument within the treated and the untreated (Robins 1989;
Herna´n and Robins 2006).
In the treatment switching literature, naive methods include excluding patients
who switch, censoring patients who switch, and using the treatment as a time-varying
covariate in a regression model. See Morden et al. (2011) for a review. Excluding
switchers results in a comparison of all units who receive the treatment to units who
are assigned to the control and do not switch. This analysis compares groups that
are not formed by randomization, and therefore may produce heavily biased results
unless the switching behavior is completely at random. Censoring the survival time
at switch relies on the assumption that the switching status is ignorable, i.e., the
22
prognosis of patients who switch is equal to that of patients who do not switch.
This assumption is untenable in studies with non-ignorable switching behavior. An
alternative approach considers the treatment as a time-varying covariate and includes
a time-varying indicator for the treatment received in a (Cox proportional hazards)
model. It is difficult to interpret the regression coefficients in these models (Fisher and
Lin 1999), especially their relationships with causal effects of interest. Moreover, this
model-based approach compares groups that are not formed by treatment assignment,
and thus it loses the benefits of randomization and can bias the estimates.
More sophisticated approaches address treatment switching by reconstructing the
outcome a unit would have had if s/he had not switched. These are inverse prob-
ability of censoring weighting (IPCW) methods, marginal structural models, and
rank-preserving structural failure time (RPSFT) models. The IPCW approach cen-
sors the switchers at the time point of switching and weights the subjects inversely
proportional to their probability to switch (Robins and Finkelstein 2000). Marginal
structural models impose structure on potential outcomes that would have been ob-
served under different treatment histories (Hernan et al. 2000). A key assumption
underlying these approaches is that the switching status is independent of the switch-
free outcomes conditional on the observed covariates. Obviously, the plausibility of
this assumption rests on the information contained in the covariates. It is worth not-
ing that the IPCW approach is generally not applicable if no pre-treatment variable
is available as in our synthetic study. Moreover when the covariates are strong pre-
dictors of the switching behavior, the estimated switching probability will be close to
zero or one for some units, and the weights can be large. As a result, in such settings
IPCW estimators can be sensitive to minor changes in the specification of the model
for the probability to switch.
The RPSFT model relates the observed survival time for each individual to the
23
time-to-event that would have been observed for that individual if s/he had never
received the treatment. The RPSFT model is rank preserving in the sense that, given
any two patients, i and i′, if patient i survives longer than patient i′ under a treatment
regime, than i survives longer than i′ under another treatment regime. This approach,
initially proposed by Robins and Tsiatis (1991) and further developed by White et al.
(1999), explicitly assumed that the time-varying treatment received status was the
actual intervention and the random treatment assignment acted as an instrumental
variable. Because the instrumental variable is binary, Robins and Tsiatis (1991) and
White et al. (1999) required a model linking the potential outcome and the observed
outcome by a scalar parameter. This scalar parameter is a real value by which each
patient’s baseline lifetime would be extended by the treatment, regardless of when
the patient eventually switches. Therefore, the scalar parameter is the causal effect of
interest, which is assumed to be the same for all patients regardless of the switching
time. The assumption that the treatment effect is constant allows one to extrapolate
treatment effects across different sub-populations of units (i.e., from non-switchers to
switchers irrespective of their switching time). Along this line, Walker et al. (2004)
and Zhang and Chen (2016) further imposed additional parametric assumptions.
Other researchers have focused on modeling the observed data using parametric
or semiparametric approaches (Zeng et al. 2011; Chen et al. 2013). However, they
usually rely on strong assumptions, like that there exists no relation between pa-
tient’s prognosis and switching behavior. Clearly, the switching status of the units in
the control group contains important post-treatment information, which is useful to
characterize treatment effect heterogeneity. Shao et al. (2005) realized this problem
and proposed a model incorporating the “switching effect.” However, as pointed by
White (2006), in their likelihood-based inference, Shao et al. (2005) again assumed
independence of the switching time and the survival time.
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4.1. Connection to the noncompliance literature
Treatment switching is a general form of the noncompliance problem. Consider the
case where the switching time of the units under control arm is either within a short
time period or never happens, i.e., Si(0) ∈ {S} ∪ [0, ] with  > 0 being a number
smaller than any survival time or censoring time. Some units immediately switch
to the treatment arm after the assignment of the treatment. In this case, treatment
switching is equivalent to the so-called all-or-none compliance problem (Angrist et al.
1996; Frangakis and Rubin 1999). A non-switcher, Si(0) = S, and a switcher, Si(0) ∈
[0, ], correspond to a complier and an always-taker, respectively. Therefore, DCE(y |
S) is the distributional effect for non-switchers or compliers, and DCE(y | [0, ]) is
the distributional effect for switchers or always-takers.
Because  is small, it is reasonable to assume that the treatment assignment affects
only the outcomes of compliers but not those of always-takers. This is the exclusion
restriction assumption (Angrist et al. 1996), meaning DCE(y | [0, ]) = 0 for all y.
Therefore, the complier distributional effect can be identified by
DCE(y | S) = P
{
Y obsi > y | Zi = 1
}− P {Y obsi > y | Zi = 0}
P
{
Sobsi = S | Zi = 0
} ,
the ratio of the distributional effect on the outcome divided by the proportion of
non-switchers.
4.2. Connection to partial noncompliance and dose-response
relationship
The switching status is a semi-continuous post-treatment variable, with a binary
component that classifies units into non-switchers and switchers, and a non-negative
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continuous component that classifies switchers according to their switching time. In
this subsection, we focus on the switchers, a coarsened principal stratum defined by
the union of uncountable sets.
Recently, assessing principal causal effects in the presence of continuous interme-
diate variables and infinitely many principal strata have received increasing attention
(Jin and Rubin 2008; Bartolucci and Grilli 2011; Ma et al. 2011; Schwartz et al. 2011;
Zigler and Belin 2012; Kim et al. 2017). Interest may lie either in principal causal
effects for specific unions of principal strata (such as, the average and distributional
principal causal effects in (6)–(8)) or in entire dose-response functions or surfaces
describing how the causal effect on the outcome varies as a function of the basic
principal strata membership. In our setting, the dose is the time to switching for
switchers. The average principal causal effect in (3) defines a dose-response function,
and the distributional causal effects in (2) and (5) define dose-response surfaces. They
describe how causal effects on survival time vary as functions of the dose. They are
similar to the “causal effect predictiveness surfaces” in the literature on surrogate
endpoints (e.g., Gilbert and Hudgens 2008; Zigler and Belin 2012).
Our setting is related to randomized experiments with partial compliance (Jin
and Rubin 2008; Ma et al. 2011). In particular, a monotonicity assumption holds by
design, because no unit in the treatment group can switch to control. The switching
status, Si(0), can be viewed as the level (time) of control received by unit i if assigned
to control, and (2), (3) and (5) are causal effects on survival time for units who would
comply with the assignment to the control arm for a specific amount of time, s, had
they been assigned to the control arm. Similarly, the coarsened principal causal effects
in (6)–(8) can be interpreted as causal effects in specific compliance regions (Ma et al.
2011). The principal causal effects are generally not identifiable with continuous
intermediate variables. Flexible parametric (e.g., Jin and Rubin 2008, 2009; Ma
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et al. 2011; Zigler and Belin 2012) and semi-parametric models (e.g., Schwartz et al.
2011; Bartolucci and Grilli 2011; Kim et al. 2017), possibly coupled with structural
assumptions, have been developed to face the identification and estimation issues.
5. Application
5.1. Data and Intention-to-treat analyses
We illustrate our approach using a synthetic dataset produced by White et al. (2002),
which closely mimic the Concorde trial, a double-blind randomized clinical trial aimed
to evaluate the effect of immediate/active versus deferred/control treatment with zi-
dovudine in symptom-free individuals infected with HIV. See Concorde Coordinating
Committee (1994) for more details.
The data comprise n = 1000 patients with asymptomatic HIV infection. Half
the patients are randomized to immediate zidovudine and the other half to deferred
zidovudine. In principle, patients in the deferred arm should not receive zidovudine
until they progress to AIDS-related complex (ARC) or AIDS. Nevertheless, some
patients in the deferred arm are allowed to switch to the active treatment arm starting
zidovudine before the onset of ARC or symptoms of HIV on the basis of persistently
low CD4 cell counts. The outcome, Y , is time-to-disease progression or death. The
survival time and the switching status are subject to censoring. The trial lasted 3
years, with staggered entry over the first 1.5 years, therefore the censoring time ranges
from 1.5 to 3 years. The data do not include any pre-treatment covariates.
Table 2 presents summary statistics. The upper panel in Table 2 provides some
insight that being assigned to immediate versus deferred treatment with zidovudine
increases survival time, but this simple comparison between survival times under
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Table 2: Synthetic Concorde data: Descriptive statistics
Variable All Zi = 0 Zi = 1
Sample size (1000) (500) (500)
Treatment assignment (Zi) 0.5 0 1
I{Sobs ≤ Ci} = 0 − 0.62 −
Switching time (S˜obsi ) − 1.55 −
I{Y obsi ≤ Ci} = 0 0.69 0.66 0.71
Survival time (Y˜ obsi ) 1.93 1.89 1.97
Zi = 0
I{Y obsi ≤ Ci} = 1 Y˜ obs = Ci
S˜obs = Ci I{Sobsi ≤ Ci} = 1 S˜obs = Ci
Variable (Si(0) = S) (Si(0) ∈ R+) (Si(0) ∈ {S} ∪ R+)
Sample size (119) (189) (192)
Treatment assignment (Zi) 0 0 0
I{S˜obsi = S} 1 0 −
I{Sobs ≤ Ci} = 0 1 0 1
Switching time (S˜obsi ) − 1.24 2.11∗
I{Y obs ≤ Ci} = 0 0 0.74 1
Survival time (Y˜ obsi ) 1.16 2.14 2.11
∗
∗Average censoring time
treatment and control cannot be even interpreted as the average causal effect of the
assignment due to the presence of censoring. Figure 2(a) shows the Kaplan–Meier
estimates of the survival functions. The survival function under treatment dominates
the one under control. This suggests that being assigned to immediate treatment
is beneficial, although the difference between the two survival curves is quite small.
The comparison between the survival curves provides a non-parametric estimate of
the intention-to-treat effect. Nevertheless, to assess the effect of immediate versus
deferred treatment with zidovudine, we cannot ignore information on the switching
status.
To further stress this point, we first conduct a Bayesian model-based intention-to-
treat analysis, which compares survival times by assignment, ignoring the switching
status (see the estimands in (1) and (2)). We assume that Yi(0) and Yi(1) marginally
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follow Weibull distributions, with parameters (αY , βY ), and (νY , γY ), respectively,
where αY , νy > 0, and βY , γY ∈ R. Therefore, the causal estimands in (1) and (2)
become
ACE = E[Yi(1)]− E[Yi(0)] = exp
{
−γy
νy
}
Γ
(
1 +
1
νy
)
− exp
{
−βy
αy
}
Γ
(
1 +
1
αy
)
,
DCE(y) = GY (1)(y)−GY (0)(y) = exp{−eγY yνY } − exp{−eβY yαY }, (y ∈ R+),
where Γ(·) is the Gamma function. We conduct Bayesian inference using Gamma
prior distributions with shape parameter 1 and scale parameter 10 000, and thus with
mean 10 000 and variance 10 0002, for αY and νY , and Normal prior distributions with
zero mean and variance 10 000 for βY and γY . The estimate of the average causal ef-
fect is approximately 0.43, with a rather wide 95% posterior credible interval covering
zero. Although the posterior probability that this effect is positive is relatively high
(approximately 0.82), there is very little evidence that being assigned to immediate
treatment with zidovudine increases the average survival time. Similarly, the esti-
mated distributional causal effects are positive and increase monotonically over time,
but there is little difference between survival curves, with the 95% posterior credible
intervals always covering zero. See Figure 2(b) showing the posterior medians and
95% posterior credible intervals of the distributional causal effects. Thus, there is ev-
idence that immediate treatment with zidovudine extends life in individuals infected
with HIV, but the estimated effects are small and statistically negligible. Neverthe-
less, it is sensible to expect that causal effects are heterogeneous across non-switchers
and switchers, or more generally across principal strata, making the intention-to-treat
analysis an inadequate summary of the evidence in the data for the efficacy of the
treatment.
To overcome the limitations of the intention-to-treat analysis, we move forward
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P
{
Y˜ obsi > y | Zi
}
DCE(y) = P {Y (1) > y} − P {Y (0) > y}
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(a) Kaplan–Meier estimates of (b) Bayesian analysis using
the survival functions Weibull models
Figure 2: Intention-to-treat analysis: In the left subfigure, the solid line corresponds
to the control and the dashed line corresponds to the treatment. In the right subfigure,
the solid line corresponds to the posterior median and the dashed lines correspond to
the 95% posterior credible interval.
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to conducting Bayesian inference on principal causal effects using the framework and
the parametric assumptions introduced in Section 3.
5.2. Bayesian principal stratification analysis
As a starting point, we assume κ = 0, i.e., Yi(0) and Yi(1) are independent given
Si(0). We simulate the posterior distributions of the causal estimands of interest using
three independent chains from different starting values. We run each chain for 125 000
iterations, discarding the first 25 000 iterations and saving every 20th iteration. The
Markov chains mix well. We combine the three chains and use the remaining 15 000
iterations to draw inference. See the Supplementary Material for details on model
and prior specification, posterior distribution of the model parameters, the MCMC
algorithm and convergence checks.
Based on the posterior medians, on average, immediate treatment with zidovudine
increases survival time for non-switchers by 1.78 years, from 2.02 under deferred
treatment with zidovudine to 3.85 years under immediate treatment with zidovudine.
The 95% posterior credible interval (0.39, 4.78) only comprises positive values. The
distributional causal effects for non-switchers are positive, and the 95% posterior
credible intervals do not cover zero, unless for survival times less than 0.35 (about 4
months) where, however, the lower bound is very close to zero. In Figure 3, DCE(y |
S) increases sharply over time from 0 to 0.28 (approximately 3 months and half) up
to y = 2.5 years, with relatively narrow posterior credible intervals including only
positive values from survival time greater than y = 0.35. The distributional causal
effect DCE(y | S) levels off after 2.5 years around 0.28 years with rather wide 95%
posterior credible intervals. Thus, there is evidence that immediate versus deferred
treatment with zidovudine increases survival time for non-switchers.
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Figure 3: Principal stratification analysis: Posterior median (solid line) and 95%
posterior credible interval (dashed lines) of the distributional causal effects for non-
switchers
The interpretation of the results for switchers deserves some care. For switchers,
Yi(1) is the value of survival if they were assigned and actually exposed to the active
treatment. The potential outcome under assignment to control, Yi(0), is the value of
survival if switchers were initially assigned to the control treatment, and thus they
were exposed to the control treatment up to time of switching, e.g., s, s ∈ R+, and
exposed to the active treatment from the time of switching, s, onward. Therefore
principal causal effects for switchers at time s compare the potential outcome that
would have been happened if they had been initially assigned to treatment and the
potential outcome that would have been happened if they had been initially assigned
to control and received control treatment up to time s, and active treatment from s
onward.
The average causal effects for switchers are very small and statistically negligible
irrespective of the time to switching. See Figure 4(a). Therefore, the assignment
to immediate treatment with zidovudine does not affect the average survival time of
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patients who would have switch to zidovudine before the onset of ARC or symptoms
of HIV, had they been assigned to deferred treatment with zidovudine. We can
interpreter these results as evidence that for switchers starting to take the active
treatment before the onset of ARC or symptoms of HIV is beneficial, in the sense
that their survival is the same as if they had received the active treatment from time
of assignment.
We focus on the conditional distributional causal effects for switchers and relegate
the results on the (unconditional) distributional causal effects to the Web Supplemen-
tary Material. Figure 4(b) shows that the conditional distributional causal effects are
always positive and show a tread increase throughout the years irrespective of the time
to switching. Nevertheless, the later the time of switching, the smaller the effects are.
Therefore the distributional causal effects for switchers are highly heterogeneous with
respect to the switching time. This seems plausible scientifically. For example, pa-
tients switch later because their CD4 cell counts remain sufficiently high for a longer
time period. Therefore, early switchers comprise weaker patients, and spending even
a short spell of time under control may be very harmful for them. Under this mecha-
nism, the benefits of immediate versus deferred treatment with zidovudine time will
be bigger for early switcher, i.e., the conditional distributional causal effects for early
switchers will be larger than late switchers. For patients who would switch later than
2 years had they been assigned to deferred treatment with zidovudine, conditional
distributional causal effects are statistically negligible: the posterior credible inter-
vals, which are not shown to avoid to make Figure 4(b) difficult to read, always cover
zero. Thus taking the active treatment either from the beginning or later on does not
affect the survival for later switchers. In a sense, we can say that switching for them
is beneficial in that their survival time when assigned control is the same as when
assigned treatment.
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(a) ACE(s), s ∈ R+ (b) cDCE(y | s)
with 95% credible interval for s = 0.25, 0.50, . . . , 2.50, 2.75
Figure 4: Posterior medians of principal causal effects for switchers
5.3. Sensitivity Analysis to κ
In the last subsection, we fix κ = 0. We now conduct a sensitivity analysis to κ,
the partial association between Yi(1) and Yi(0) given the switching status, Si(0). We
derive the posterior distribution of the causal estimands for κ = 0, 0.25, 0.5, 0.75, 1,
using the same priors for other parameters as in Section 5.2. Table 3 and Figure 5
present the results.
In Table 3 and Figure 5(a) the posterior medians of the average causal effects and
of the distributional causal effects for non-switchers change only slightly by varying
κ ∈ [0, 1]. Values of κ mainly affect the posterior variability of the causal estimands,
leading to tighter 95% posterior credible intervals with κ > 0. The higher the value
of κ, the tighter the 95% posterior credible intervals are. The causal conclusions re-
main substantially unchanged: immediate versus deferred treatment with zidovudine
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Table 3: Principal stratification analysis: Posterior median and 95% posterior credible
interval for causal estimands for non-switchers for different values of κ
κ E[Yi(0) | Si(0) = S] E[Yi(1) | Si(0) = S] ACE(S)
κ = 0 2.02 (1.44; 2.97) 3.85 (2.41; 6.94) 1.78 (0.39; 4.78)
κ = 0.25 2.04 (1.78; 2.39) 4.18 (3.37; 5.46) 2.13 (1.29; 3.41)
κ = 0.50 2.04 (1.79; 2.39) 3.99 (3.32; 5.00) 1.94 (1.28; 2.95)
κ = 0.75 2.04 (1.78; 2.38) 3.82 (3.28; 4.59) 1.77 (1.28; 2.51)
κ = 1 2.15 (1.88; 2.55) 4.27 (3.72; 5.01) 2.10 (1.66; 2.76)
increases survival time for non-switchers, both on average and over time, irrespective
of the value of κ.
Results for switchers display some sensitivity to κ. Figure 5(b) shows that the
estimates of the average causal effects for switchers are statistically negligible as
those we obtained for κ = 0 for κ = 0.75, although for κ = 0.75 the 95% posterior
credible intervals are much smaller. We find strong evidence that immediate versus
deferred treatment with zidovudine increases the average survival time for switchers
irrespective of the time to switching for κ = 1, under which, monotonicity Yi(1) ≥
Yi(0) holds. When κ = 0.25 or κ = 0.5, we find some evidence that immediate versus
deferred treatment with zidovudine decreases survival time for switchers who switch
later than 2 and 0.75 years, respectively. The 95% posterior credible intervals for
ACE(s), with s ≥ 2 and s > 0.75, include only negative values.
Figure 5(c) compares the posterior medians of cDCE(y | s) for s = 0.25, 0.50, . . . ,
2.50, 2.75. From Figure 5(c), the posterior medians of cDCE(y | s) show a tread
increase throughout the years at κ = 0, but have an asymmetrical inverted U-shape
skewed to the right at κ ∈ {0.25, 0.5, 0.75, 1}, at least for switchers who would switch
relatively soon.
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κ = 0 κ = 0.25 κ = 0.5 κ = 0.75 κ = 1
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(b) ACE(s), s ∈ R+
Time to event
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.
00
0.
05
0.
10
0.
15
0.
20
Time to event
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.
00
0.
05
0.
10
0.
15
0.
20
Time to event
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.
00
0.
05
0.
10
0.
15
0.
20
Time to event
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.
00
0.
05
0.
10
0.
15
0.
20
Time to event
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.
00
0.
05
0.
10
0.
15
0.
20
(c) cDCE(y | s) for s = 0.25, 0.50, . . . , 2.50, 2.75
Figure 5: Principal causal effects: Posterior median (solid line) and 95% posterior
credible interval (dashed lines), for different values of κ
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5.4. Sensitivity Analysis to the Prior Distribution for λ
Previous results are obtained using a weakly informative prior distribution for λ,
namely, N(0, 104). We assess the sensitivity of the results to the prior specification
for λ, by specifying three alternative priors. We consider two normal priors with
smaller variances, N(0, 1) and N(0, 10), and an improper prior uniformly over the
whole real line. The hyperparameters of the prior distributions for the other model-
parameters are set to the same values as in Section 5.2. We focus on the scenario
with κ = 0. Table 4 and Figure 6 present the results, showing that inference is robust
with respect to the prior specification for λ. We see that the posterior distribution
of the causal estimands changes only slightly using different prior distributions for
λ. Moreover, the posterior distribution of λ is robust to different prior specifications.
The posterior mean of λ remains approximately 0.10, with standard deviation of 0.17
irrespective of the prior specification. Although the 95% posterior credible intervals
cover 0, the posterior probability that the parameter λ is positive ranges between
70.4% and 71.8% using different priors. Thus, there appears to be some evidence
that the death hazard increases as the time of switching increases, suggesting that
the residual life time after switching is shorter for patients who would switch later
than for patients who would switch earlier.
5.5. Model Check: Posterior Predictive P -Values
Previous results are based on the parametric modeling assumptions and weakly infor-
mative priors. It is important to conduct model checking. We use posterior predictive
p−values to evaluate parametric assumptions. We find no evidence against the model.
To save space in the main text, we relegate the details to the Web Supplementary
Material.
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λ ∼ N(0, 1) λ ∼ N(0, 10) λ ∼ N(0, 10 000) λ ∼ Uniform(R)
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(b) ACE(s), s ∈ R+
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(c) cDCE(y | s) for s = 0.25, 0.50, . . . , 2.50, 2.75
Figure 6: Principal causal effects: Posterior median (solid line) and 95% posterior
credible interval (dashed lines) for different prior distributions for λ with κ = 0
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Table 4: Principal stratification analysis: Summaries of posterior distributions of
causal estimands for non-switchers for different prior distributions for λ (κ = 0)
λ ∼ N(0, 1) λ ∼ N(0, 10)
95% PCI 95% PCI
Estimand 0.50 0.025 0.975 0.50 0.025 0.975
E[Yi(0) | Si(0) = S] 2.02 1.43 3.00 2.02 1.43 2.99
E[Yi(1) | Si(0) = S] 3.84 2.41 6.95 3.85 2.42 6.90
ACE(S) 1.78 0.41 4.76 1.79 0.39 4.74
λ ∼ N(0, 10 000) λ ∼ Uniform(R)
95% PCI 95% PCI
Estimand 0.50 0.025 0.975 0.50 0.025 0.975
E[Yi(0) | Si(0) = S] 2.02 1.44 2.97 2.03 1.43 2.99
E[Yi(1) | Si(0) = S] 3.85 2.41 6.94 4.08 2.48 7.70
ACE(S) 1.78 0.39 4.78 2.01 0.45 5.49
6. Discussion
We have proposed to use principal stratification to assess causal effects in random-
ized clinical trials with one-sided treatment switching. Principal causal effects allow
for treatment comparisons with proper adjustment for the post-treatment switching
behaviour. Principal causal effects for non-switchers provide information on the pure
effect of the treatment, because they are essentially compliers who would take the
treatment assigned and would not switch. Principal causal effects provide valuable
information on treatment effect heterogeneity across different types of units: non-
switchers and switchers, and switchers at different time points. We have illustrate
this using a synthetic dataset based on the Concorde trial.
It is extremely challenging to infer principal causal effects within strata defined by
the switching behaviour, because the partially observed switching time generates a
continuum of principal strata. With one-sided treatment switching, where the switch-
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ing time may be censored, we observed the switching status only for some units in the
control arm. We do not observed the switching status for any unit in the treatment
arm. In the treatment arm, the observed distributions are infinite mixtures of latent
principal strata. As an initial exploration, we adopt a parametric Bayesian approach.
Our future research will focus on alternative and more flexible specifications, includ-
ing Bayesian non-parametric models (Ibrahim et al. 2001; Schwartz et al. 2011; Zigler
and Belin 2012; Kim et al. 2017).
Two parameters, κ and λ, are weakly identified in our model. The former de-
scribes the partial association between the two potential survival outcomes given
the switching status, and the latter describes the association between the potential
survival outcome under treatment and the switching status. We conduct sensitivity
analyses, by investigating how the posterior distributions of causal estimands change
under different κ values and under different prior specifications for λ. In the synthetic
Concorde data, our analysis appears to be robust with respect to prior specifications
for λ but displays some sensitivity to κ.
Background covariate information is valuable in various ways. First, if pre-
treatment variables enter the treatment assignment mechanism, such as in stratified
randomized experiments, analyses must be conditional on them. Second, in com-
pletely randomized experiments, although pre-treatment covariates do not enter the
treatment assignment mechanism, they can make parametric assumptions more plau-
sible. Moreover, they can improve prediction of the missing potential outcomes and
lead to more precise inferences. Third, in the principal stratification analysis, relevant
information could also be obtained looking at the distribution of baseline character-
istics within each principal stratum. The ability to characterize the latent subgroups
of patients in terms of their background characteristics can provide insights on the
type of patients for which the treatment is more effective. Therefore, covariates might
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help explaining the heterogeneity of the effects across principal strata defined by the
switching status.
In clinical trials involving duration outcomes, censoring may be due other events
such as dropout and loss to follow-up. We have assumed ignorability of censoring
mechanism, which implies that the censoring mechanism is independent of the sur-
vival potential outcomes and the switching time. A valuable topic for future research
is to relax the assumption of ignorable censoring mechanism addressing the problem
of treatment switching with non-ignorable random censoring. An appealing approach
to deal with non-ignorable random censoring is to extend the principal stratifica-
tion analysis we present here to multiple intermediate variables, the switching status
and the censoring time, considering alternative sets of assumptions on the censoring
mechanism and investigating the sensibility of the results with respect to them.
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Coarsened principal causal effects
We define coarsened principal causal effects in Equations (??), (??) and (??) in the main text.
The simplest example is A = R+ and the causal effects for all switchers are
ACE(R+) = E [Yi(1) | Si(0) ∈ R+]− E [Yi(0) | Si(0) ∈ R+] ,
DCE(y | R+) = P {Yi(1) > y | Si(0) ∈ R+} − P {Yi(0) > y | Si(0) ∈ R+} ,
cDCE(y | R+) = P {Yi(1) > y | Yi(1) ≥ Si(0), Si(0) ∈ R+}
−P {Yi(0) > y | Yi(1) ≥ Si(0), Si(0) ∈ R+} .
If A = [0, s], then the causal effects for units that switch earlier than time s are
ACE([0, s]) = E [Yi(1) | Si(0) ≤ s]− E [Yi(0) | Si(0) ≤ s] ,
DCE(y | [0, s]) = P {Yi(1) > y | Si(0) ≤ s} − P {Yi(0) > y | Si(0) ≤ s} ,
cDCE(y | [0, s]) = P {Yi(1) > y | Yi(1) ≥ Si(0), Si(0) ≤ s}
−P {Yi(0) > y | Yi(1) ≥ Si(0), Si(0) ≤ s} .
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If A = (s,+∞), then the causal effects for units that switch later than time s are
ACE((s,+∞)) = E [Yi(1) | Si(0) > s]− E [Yi(0) | Si(0) > s] ,
DCE(y | (s,+∞)) = P {Yi(1) > y | Si(0) > s} − P {Yi(0) > y | Si(0) > s} ,
cDCE(y | (s,+∞)) = P {Yi(1) > y | Yi(1) ≥ Si(0), Si(0) > s}
−P {Yi(0) > y | Yi(1) ≥ Si(0), Si(0) > s} .
Bayesian Inference
Let Z, C, S(0), Y (0), and Y (1) be n-vectors with ith elements equal to Zi, Ci, Si(0), Yi(0), and Yi(1),
respectively. Let X be a n × K matrix with ith row equal to Xi. The joint probability (density) func-
tion of these random variables is P {Z,C,S(0),Y (0),Y (1),X} = P {C,S(0),Y (0),Y (1),X}P {Z} under
Assumption ??. This allows us to ignore the model of P {Z}.
We assume that P {C,S(0),Y (0),Y (1),X} is unit-exchangeable. By appealing to de Finetti’s theorem
(De Finetti 1937), there exists an unknown parameter vector θ with prior distribution P (θ) such that
P {C,S(0),Y (0),Y (1),X}
=
∫ n∏
i=1
P {Ci, Si(0), Yi(0), Yi(1), Xi | θ}P (θ)dθ
=
∫ n∏
i=1
P {Xi | θ}P {Si(0) | Xi;θ}P {Yi(0) | Si(0), Xi;θ}
P {Yi(1) | Yi(0), Si(0), Xi;θ}P {Ci | Si(0), Yi(0), Yi(1), Xi;θ}P (θ)dθ.
We condition on the observed distribution of covariates, and assume that the parameters of the distribu-
tion of covariates are a priori independent of the other parameters. Then we do not need to model P {Xi | θ}.
Under Assumption ??, P {Ci | Si(0), Yi(0), Yi(1), Xi;θ} = P {Ci | Xi;θ}. Assuming that the parameters of
the censoring mechanism are a priori independent of the other parameters, we can then ignore the model of
P {Ci | Si(0), Yi(0), Yi(1), Xi;θ}. Therefore, Bayesian inference for principal stratification involves two sets
of models: one for the principal strata defined by the switching status, Si(0), given the covariates , Xi, and
the other for the distribution of potential survival times Yi(0) and Yi(1) conditional on the switching status
and covariates, Xi.
First, we postulate a two-part model for Si(0). Let pi(xi) = P
{
Si(0) = S | Xi = xi;θ
}
be the probability
of being a non-switcher, and let fS(0) (· | xi) = fS(0)(· | Si(0) ∈ R+, Xi = xi;θ) and GS(0)(· | xi) =
P {Si(0) > · | Si(0) ∈ R+, Xi = xi;θ} denote the probability density function and the survival function of
2
Table 1: Probability density functions, hazard functions and survival functions of the potential survival times
conditional on the switching status under non-informative type one censoring.
Variable
Probability density function, hazard function and survival function
Si(0) | Si(0) ∈ R+
fS(0) (·) = fS(0)(· | Si(0) ∈ R+;θ)
hS(0) (·) = hS(0)(· | Si(0) ∈ R+;θ)
GS(0)(·) = P {Si(0) > · | Si(0) ∈ R+;θ}
Yi(0) | Si(0) = S, Xi = xi
fSY (0) (· | xi) = fY (0)(· | Si(0) = S, Xi = xi;θ)
hSY (0) (· | xi) = hY (0)(· | Si(0) = S, Xi = xi;θ)
GSY (0)(· | xi) = P
{
Yi(0) > · | Si(0) = S, Xi = xi;θ
}
Yi(0) | Si(0) = s,Xi = xi (s ∈ R+)
fY (0) (· | s, xi) = fY (0)(· | Si(0) = s,Xi = xi;θ)
hY (0) (· | s, xi) = hY (0)(· | Si(0) = s,Xi = xi;θ)
GY (0)(· | s, xi) = P {Yi(0) > · | Si(0) = s,Xi = xi;θ}
Yi(1) | Si(0) = S, Yi(0) = y0, Xi = xi
fSY (1) (· | y0, xi) = fY (1)(· | Si(0) = S, Yi(0) = y0, Xi = xi;θ)
hSY (1) (· | y0, xi) = hY (1)(· | Si(0) = S, Yi(0) = y0, Xi = xi;θ)
GSY (1)(· | y0, xi) = P
{
Yi(1) > · | Si(0) = S, Yi(0) = y0, Xi = xi;θ
}
Yi(1) | Si(0) = s, Yi(0) = y0, Xi = xi (s ∈ R+)
fY (1) (· | s, y0, xi) = fY (1)(· | Si(0) = s, Yi(0) = y0, Xi = xi;θ)
hY (1) (· | s, y0, xi) = hY (1)(· | Si(0) = s, Yi(0) = y0, Xi = xi;θ)
GY (1)(· | s, y0, xi) = P {Yi(1) > · | Si(0) = s, Yi(0) = y0, Xi = xi;θ}
the switching time for switchers (that is, given that Si(0) does not take on value S). Because we focus
on time-to-event variables, it is useful to introduce the notation for hazard functions. Let hS(0) (· | xi) =
hS(0)(· | Si(0) ∈ R+, Xi = xi;θ) be the hazard function of Si(0) for switchers, which satisfies fS(0) (· | xi) =
hS(0) (· | xi) × GS(0)(· | xi). Second, we specify a model for the joint conditional distribution of Yi(0) and
Yi(1) given Si(0) and Xi, by factorizing it as the product of the conditional distribution of Yi(0) given Si(0)
and Xi, and the conditional distribution of Yi(1) given Yi(0), Si(0) and Xi. Table 1 shows the notation for
the probability density functions, hazard functions and the survival functions of the potential survival times
P{Yi(0) | Si(0), Xi} and P{Yi(1) | Yi(0), Si(0), Xi}.
Let Dobs =
[
Z,C, S˜obs, I{Sobs ≤ C}, Y˜ obs, I{Yobs ≤ C}
]
be an n × 6 matrix, with ith row equal to
3
Dobsi = [Zi, Ci S˜
obs
i , I{Sobsi ≤ Ci}, Y˜ obsi , I{Y obsi ≤ Ci}]. The complete-data contain the observed dataX and
Dobs, as well as the vector of switching statuses S∗(0) with the ith element S∗i (0) = (1− Zi)[S˜obsi I{Si(0) ∈
R+}+ S I{Si(0) = S}] + ZiSi(0) and the vector of survival times under control Y ∗(0) with the ith element
Y ∗i (0) = (1 − Zi)Y˜ obsi + ZiYi(0). We can then write the observed-data likelihood function in terms of the
observed data as:
L
{
θ |X,Dobs
}
=
∏
i:Zi=0,I{Sobsi ≤Ci}=0,I{Y obsi ≤Ci}=1
pi(Xi) f
S
Y (0)
(
Y obsi | Xi
)
(1)
×
∏
i:Zi=0,I{Sobsi ≤Ci}=1,I{Y obsi ≤Ci}=0
[1− pi(Xi)] fS(0)
(
Sobsi | Xi
) ·GY (0) (Ci | Sobsi , Xi)
×
∏
i:Zi=0,I{Sobsi ≤Ci}=1,I{Y obsi ≤Ci}=1
[1− pi(Xi)] fS(0)
(
Sobsi | Xi
)
fY (0)
(
Y obsi | Sobsi , Xi
)
×
∏
i:Zi=0,I{Sobsi ≤Ci}=0,I{Y obsi ≤Ci}=0
pi(Xi)G
S
Y (0) (Ci | Xi) + [1− pi(Xi)] GS(0) (Ci | Xi) · 1
×
∏
i:Zi=1,I{Y obsi ≤Ci}=1
[
pi(Xi)
∫
R+
fSY (1)
(
Y obsi | Yi(0) = y0, Xi
)
dy0+
[1− pi(Xi)]
∫
R+
∫ +∞
s
fY (1)
(
Y obsi | Si(0) = s, Yi(0) = y0, Xi
)
fY (0) (y0 | Si(0) = s,Xi) fS(0) (s | Xi) dy0 ds
]
×
∏
i:Zi=1,I{Y obsi ≤Ci}=0
[
pi
∫
R+
GSY (1) (Ci | Yi(0) = y0, Xi) dy0+
[1− pi(Xi)]
∫
R+
∫ +∞
s
GY (1) (Ci | Si(0) = s, Yi(0) = y0, Xi) fY (0) (y0 | Si(0) = s,Xi) fS(0) (s | Xi) dy0 ds
]
The posterior distribution of θ based on the complete-data is
P
{
θ |X,Dobs,S∗(0),Y ∗(0)
}
∝ P (θ)
×
∏
i:Zi=0,Si(0)=S
pi(Xi) f
S
Y (0)
(
Y obsi | Xi
)I{Y obsi ≤Ci}GSY (0) (Ci | Xi)I{Y obsi >Ci}
×
∏
i:Zi=0,Si(0)∈R+
[1− pi(Xi)] GS(0) (Ci | Xi)I{S
obs
i >Ci}
[
fS(0)
(
Sobsi | Xi
)
fY (0)
(
Y obsi | Sobsi , Xi
)I{Y obsi ≤Ci}GY (0) (Ci | Sobsi , Xi)I{Y obsi >Ci}]I{Sobsi ≤Ci}
×
∏
i:Zi=1,Si(0)=S
pi(Xi) f
S
Y (1)
(
Y obsi | Yi(0), Xi
)I{Y obsi ≤Ci}GSY (1) (Ci | Yi(0), Xi)I{Y obsi >Ci}
×
∏
i:Zi=1,Si(0)∈R+
[1− pi(Xi)] fS(0) (Si(0) | Xi)
fY (1)
(
Y obsi | Si(0), Yi(0), Xi
)I{Y obsi ≤Ci}GY (1) (Ci | Si(0), Yi(0), Xi)I{Y obsi >Ci} .
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Parametric assumptions
Weibull distribution
A Weibull random variable T with parameters (α, η) has pdf
f(t) =

αηtα−1 exp{−ηtα} for t > 0, α > 0, η > 0,
0 otherwise.
The survivor function, the hazard function and the cumulative hazard function of T are
G(t) = exp{−ηtα}, h(t) = αηtα−1, H(t) =
∫ t
0
h(u) du = ηtα.
Under the parameterization β = log(η), we have
f(t) = αtα−1 exp{β − eβtα},
G(t) = exp{−eβtα}, h(t) = αtα−1eβ H(t) = eβtα.
Sub-model for Si(0) for switchers
Si(0) | Si(0) ∈ R+, Xi ∼Weibull (αS , βS +X ′iηS), αS > 0, βS ∈ R, ηS ∈ RK :
fS(0)(s | xi) = αSsαS−1 exp{[βS + x′iηS ]− eβS+x
′
iηSsαS},
hS(0)(s | xi) = αSsαS−1 exp{βS + x′iηS}, GS(0)(s | x′i) = exp{−eβS+x
′
iηSsαS}.
Sub-model for Yi(0) for non-switchers
Yi(0) | Si(0) = S, Xi ∼Weibull
(
α¯Y , β¯Y +X
′
iη¯Y
)
, α¯Y > 0, β¯Y ∈ R and η¯Y ∈ RK :
fSY (0)(y | xi) = α¯Y yα¯Y −1 exp{[β¯Y + x′iη¯Y ]− eβ¯Y +x
′
iη¯Y yα¯Y },
hSY (0)(y | xi) = α¯Y yα¯Y −1 exp{β¯Y + x′iη¯Y }, GSY (0)(y | xi) = exp{−eβ¯Y +x
′
iη¯Y yα¯Y }.
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Sub-model for Yi(0) for switchers
Given Si(0) ∈ R+, Yi(0) | Si(0), Xi ∼ Si(0) + Weibull (αY , βY + λ0 logSi(0) +X ′iηY ), αY > 0, βY , λ0 ∈ R,
ηY ∈ RK :
fY (0)(y |s, xi)=αY (y − s)αY −1 exp{[βY +λ0 log(s) + x′iηY ]−eβY +λ0 log(s)+x
′
iηY (y − s)αY },
hY (0)(y | s, xi) = αY (y − s)αY −1eβY +λ0 log(s)+x′iηY ,
GY (0)(y | s, xi) = exp{−eβY +λ0 log(s)+x′iηY (y − s)αY }.
Sub-model for Yi(1) for non-switchers
Yi(1) | Si(0) = S, Yi(0), Xi ∼ κYi(0) + Weibull
(
ν¯Y , γ¯Y +X
′
iζ¯
)
, κ ∈ [0, 1], ν¯Y > 0, γ¯Y ∈ R, ζ¯ ∈ RK :
fSY (1)(y | y0, xi) = ν¯Y (y − κy0)ν¯Y −1 exp{[γ¯Y + x′iζ¯]− eγ¯Y +x
′
iζ¯(y − κy0)ν¯Y },
hSY (1)(y | y0, xi) = ν¯Y (y − κy0)ν¯Y −1eγ¯Y +x
′
iζ¯ ,
GSY (1)(y | y0, xi) = exp{−eγ¯Y +x
′
iζ¯(y − κy0)ν¯Y }.
Sub-model for Yi(1) for switchers
Yi(1) | Si(0), Yi(0), Xi ∼ κYi(0) + Weibull (νY , γY + λ logSi(0) +X ′iζ), κ ∈ [0, 1], νY > 0, γY , λ1 ∈ R,
ζ ∈ RK :
fY (1)(y |s, y0, xi)=νY (y−κy0)νY −1 exp{[γY +λ1 log(s)+x′iζ]−eγY +λ1 log(s)+x
′
iζ(y − κy0)νY },
hY (1)(y | s, y0, xi) = νY (y − κy0)νY −1eγY +λ1 log(s)+x′iζ ,
GY (1)(y | s, y0, xi) = exp{−eγY +λ1 log(s)+x′iζ(y − κy0)νY }.
Prior distributions
We assume that the parameters are a priori independent, and impose proper but weakly informative priors
on them. Under the model specification introduced in Section ?? of the main text, we propose to use
Normal prior distributions for the parameters of the logistic regression model for the mixing probability
pi(Xi): (η0,η) ∼ N(µη, σ2η IK+1), where Ir is the r × r identity matrix. We use Gamma prior distribu-
tions for the shape parameters of the Weibull distributions: αS ∼ Gamma(aS , bS), α¯Y ∼ Gamma(a¯Y , b¯Y ),
αY ∼ Gamma(aY , bY ), ν¯Y ∼ Gamma(d¯Y , s¯Y ), and νY ∼ Gamma(dY , sY ). Finally we use Normal prior
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distributions for the other parameters of the Weibull distributions: βS ∼ N(µβS , σ2βS ), ηS ∼ N(µηS , σ2ηS IK);
β¯Y ∼ N(µβ¯Y , σ2β¯Y ), η¯Y ∼ N(µη¯Y , σ2η¯Y IK); βY ∼ N(µβY , σ2βY ), ηY ∼ N(µηY , σ2ηY IK); γ¯Y ∼ N(µγ¯Y , σ2γ¯Y ),
ζ¯Y ∼ N(µζ¯Y , σ2ζ¯Y IK); γY ∼ N(µγY , σ2γY ), ζY ∼ N(µζY , σ2ζY IK); and λ ∼ N(µλ, σ2λ). We use a Dirac delta
prior for the sensitivity parameter κ concentrated at a pre-fixed value κ0 ∈ [0, 1] and we assess the sensitivity
of the conclusions to different assumptions on κ, by examining how the posterior distributions of the causal
estimands change with respect to different κ0 within the range [0, 1].
Application: Model and Computational Details
Parametric Assumptions
Sub-model for the Switching Behavior
pi = E[I{Si(0) = S}] = P
(
Si(0) = S
)
and Si(0) | Si(0) ∈ R+ ∼Weibull (αS , βS), αS > 0, βS ∈ R:
fSi(0)(s) = αSs
αS−1 exp{βS − eβSsαS}
hSi(0)(s) = αSs
αS−1eβS GSi(0)(s) = exp{−eβSsαS}
Sub-model for Yi(0) | Si(0)
Yi(0) | Si(0) = S ∼Weibull
(
α¯Y , β¯Y
)
, α¯Y > 0, β¯Y ∈ R:
fSY (0)(y) = α¯Y y
α¯Y −1 exp{β¯Y − eβ¯Y yα¯Y }
hSY (0)(y) = α¯Y y
α¯Y −1eβ¯Y GSY (0)(y) = exp{−eβ¯Y yα¯Y }
and Yi(0) | Si(0) ∈ R+ ∼ Si(0) + Weibull (αY , βY + λ log(s)), αY > 0, βY ∈ R, λ ∈ R:
fY (0)(y | s) = αY (y − s)αY −1 exp{[βY + λ log(s)]− eβY +λ log(s)(y − s)αY }
hY (0)(y|s) = αY (y − s)αY −1eβY +λ log(s) GY (0)(y|s) = exp{−eβY +λ log(s)(y − s)αY
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Sub-model for Yi(1) | Yi(0), Si(0)
Yi(1) | Yi(0), Si(0) = S ∼ κYi(0) + Weibull (ν¯Y , γ¯Y ) ν¯Y > 0, γ¯Y ∈ R:
fSY (1)(y | y0) = ν¯Y (y − κy0)ν¯Y −1 exp{γ¯Y − eγ¯Y (y − κy0)ν¯Y }
hSY (1)(y | y0) = ν¯Y (y − κy0)ν¯Y −1eγ¯Y GSY (1)(y | y0) = exp{−eγ¯Y (y − κy0)ν¯Y }
and Yi(1) | Yi(0), Si(0) ∈ R+ ∼ κYi(0) + Weibull (νY , γY + λ log(s)), νY > 0, γY ∈ R, λ ∈ R:
fY (1)(y | s, y0) = νY (y − κy0)νY −1 exp{[γY + λ log(s)]− eγY +λ log(s)(y − κy0)νY }
hY (1)(y|s, y0) = νY (y − κy0)νY −1eγY +λ log(s) GY (1)(y|s, y0) = exp{−eγY +λ log(s)(y − κy0)νY }
Therefore, the entire parameter vector is θ =
[
pi, (αS , βS) ,
(
α¯Y , β¯Y
)
, (αY , βY ) , (ν¯Y , γ¯Y ) , (νY , γY ) , λ, κ
]
.
Prior distributions
Parameters are assumed to be a priori independent, with the following prior distributions. We use a conjugate
Beta prior distribution for the mixing probability pi ∼ Beta(a, b):
pi ∼ Beta(a, b) : p(pi) = Γ(a)Γ(b)
Γ(a+ b)
pia−1(1− pi)b−1
with a = b = 1. Therefore the full conditional distribution of pi is Beta with parameters a+
∑n
i=1 I{Si(0) = S}
and b+
∑n
i=1 I{Si(0) ∈ R+}.
We use Gamma priors for the shape parameters of the Weibull distributions, αS , α¯Y , αY , ν¯Y and νY ,
αS ∼ Gamma(aS , bS) : p(αS) = 1
(bS)aSΓ(aS)
αaS−1S e
−αS/bS
α¯Y ∼ Gamma(a¯Y , b¯Y ) αY ∼ Gamma(aY , bY ) ν¯Y ∼ Gamma(d¯Y , s¯Y ) νY ∼ Gamma(dY , sY )
with aS = a¯Y = aY = dY = 1, bS = b¯Y = aY = sY = 10, and d¯Y = 1.25/0.01, s¯Y = 0.01.
8
We use Normal priors for βS , β¯Y , βY , γ¯Y , γY and λY :
βS ∼ N(µS , σ2S) : p(βS) =
1√
2piσ2S
exp
{
− 1
2σ2S
(βS − µS)2
}
β¯Y ∼ N(µ¯Y , σ¯2Y ) βY ∼ N(µY , σ2Y ) γ¯Y ∼ N(m¯Y , τ¯2Y ) γY ∼ N(mY , τ2Y )
λ ∼ N(µλ, σ2λ)
with µS = µ¯Y = µY = m¯Y = mY = µλ = 0 and σ
2
S = σ¯
2
Y = σ
2
λ = 10
4, and τ¯2Y = τ
2
Y = 1.
It is worth noting that we use more informative prior distributions for the parameters νY γY and γY to
deal with the difficulty of untying the mixture of switchers and non-switchers under treatment. Because we
never observe the switching behavior for units assigned to the active treatment, there is not a unique way
to disentangle the mixture of switchers and non-switchers under treatment, and thus we can end up with
unrealistic draws for those parameters. The availability of covariates might, at least partially, address this
issue, helping to better disentangle the mixture.
Complete-(switching status) data posterior distribution
Let Dobsi =
[
Zi, Ci, S˜
obs
i , I{Sobsi ≤ Ci}, Y˜ obsi , I{Y obsi ≤ Ci}
]
denote the observed data for unit i and let
Dobs =
[
Z,C, S˜obs, I{Sobs ≤ C}, Y˜ obs, I{Yobs ≤ C}
]
be the matrix stacking observation for all units. The
complete-(switching status) data posterior distribution for the parameter vector θ =
[
pi, (αS , βS) ,
(
α¯Y , β¯Y
)
,
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(αY , βY ) , (ν¯Y , γ¯Y ) , (νY , γY ) , λ, κ = κ0], κ0 ∈ [0, 1], is
P
{
θ |Dobs,S∗(0),Y ∗(0)
}
∝
P{pi}P{αS}P{βS}P{α¯Y }P{β¯Y }P{αY }P{βY }P{ν¯Y }P{γ¯Y }P{νY }P{γY }P{λ}δκ0(κ)
×
∏
i:Zi=0,S
∗
i (0)=S
pi
[
α¯Y (Y˜
obs
i )
α¯Y−1 exp{β¯Y −eβ¯Y (Y˜ obsi )α¯Y }
]I{Y obsi ≤Ci}
exp{−eβ¯Y Cα¯Yi }1−I{Y
obs
i ≤Ci}
×
∏
i:Zi=0,S
∗
i (0)∈R+
(1− pi)
{
αS(S˜
obs
i )
αS−1 exp{βS − eβS (S˜obsi )αS}
[
αY (Y˜
obs
i −S˜obsi )αY−1 exp{[βY +λ log(S˜obsi )]− eβY+λ log(S˜
obs
i )(Y˜ obsi −S˜obsi )αY }
]I{Y obsi ≤Ci}
[
exp{−eβY +λ log(S˜obsi )(Ci − S˜obsi )αY }
]1−I{Y obsi ≤Ci}}I{Sobsi ≤Ci}{
exp{−eβS (Ci)αS}
}1−I{Sobsi ≤Ci}
×
∏
i:Zi=1,S
∗
i (0)=S
pi
[
ν¯Y (Y˜
obs
i − κY ∗i (0))ν¯Y−1 exp{γ¯Y −eγ¯Y (Y˜ obsi − κY ∗i (0))ν¯Y }
]I{Y obsi ≤Ci}
exp{−eγ¯Y (Ci − κY ∗i (0))ν¯Y }1−I{Y
obs
i ≤Ci}
×
∏
i:Zi=1,Si(0)∈R+
(1− pi)αSS∗i (0)αS−1 exp{βS−eβSS∗i (0)αS}
[
exp{−eγY +λ log(S∗i (0))(Ci − κY ∗i (0))νY }
]1−I{Y obsi ≤Ci}
[
νY (Y˜
obs
i − κY ∗i (0))νY −1 exp{[γY + λ log(S∗i (0))]− eγY +λ log(S
∗
i (0))(Y˜ obsi − κY ∗i (0))νY }
]I{Y obsi ≤Ci}
.
Details of Calculations
Note that if κ = 0, we only need to impute the missing switching status, by drawing from its conditional
distribution given (Dobs,θ); we do not need to impute Yi(0) for treated units.
The random variables S∗i (0) and Y
∗
i (0) are independent across units i = 1, . . . , n given (D
obs,θ), therefore
sampling from the distributions of (S∗(0) | Dobs,θ) (for κ = 0) and (S∗(0),Y ∗(0) | Dobs,θ) (for κ ∈ (0, 1])
for data augmentation only involves independent drawing from (S∗i (0) | Dobsi ,θ) and (S∗i (0), Y ∗i (0) | Dobsi ,θ).
Details of Calculations: κ = 0
Let (θ,S∗(0)) denote the current state of the chain, with
θ =
[
pi, (αS , βS) ,
(
α¯Y , β¯Y
)
, (αY , βY ) , (ν¯Y , γ¯Y ) , (νY , γY ) , λ, κ = 0
]
.
1. Given the parameter θ and observed data, Dobs, draw the missing data S∗i (0)
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− For control patients, we have
S∗i (0) = Si(0) =

S if Zi = 0, I{Sobsi ≤ Ci} = 0, I{Y obsi ≤ Ci} = 1
S˜obsi = S
obs
i if Zi = 0, I{Sobsi ≤ Ci} = 1, I{Y obsi ≤ Ci} ∈ {0, 1},
For control patients with I{Sobsi ≤ Ci} = 0 and I{Y obsi ≤ Ci} = 0, we have
piNS ≡ P
(
S∗i (0) = S | θ, Zi = 0, Ci, S˜obsi , I{Sobsi ≤ Ci} = 0, Y˜ obsi , I{Y obsi ≤ Ci} = 0
)
=
piGSY (0)(Ci)
piGSY (0)(Ci) + (1− pi)GSi(0)(Ci) · 1
Therefore control patients with I{Sobsi ≤ Ci} = 0 and I{Y obsi ≤ Ci} = 0 are classified as
non-switchers (S∗i (0) = S) with probability piNS and as switchers with censored switching time
(S∗i (0) = S˜
obs
i = Ci) with probability 1− piNS
− For treated patients, we never observe Si(0). We use Metropolis-Hasting steps to draw Si(0)
according to P
(
Si(0) | θ, Dobsi
)
. We draw candidate values Scandi (0) from a semi-continuous
distribution: We first draw n1 values from a Bernoulli distribution with probability pi setting
Scandi (0) = S for treated units for which we obtain a success (a positive value). For treated
units for which we obtain a failure, a missing value of Scandi (0) is then drawn from the Weibull
distribution with parameters αS and βS : Weibull (αS , βS). For each i with Zi = 1, we accept
Scandi (0), setting S
∗
i (0) = S
cand
i (0), with probability pi = min{pSi(0), 1}, with
pSi(0) =

ri if S
∗
i (0) = S, Scandi (0) = S
ri · pi
(1− pi)fS(0)(Scandi (0))
if S∗i (0) = S, Scandi (0) ∈ R+
ri ·
(1− pi)fS(0)(S∗i (0))
pi
if S∗i (0) ∈ R+, Scandi (0) = S
ri ·
fS(0)(S
∗
i (0))
fS(0)(S
cand
i (0))
if S∗i (0) ∈ R+, Scandi (0) ∈ R+
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where fS(0)(·) is the density of the proposal Weibull distribution, Weibull (αS , βS), and
ri =
P
{
θ | Dobsi , Scandi (0)
}
P
{
θ | Dobsi , S∗i (0)
} .
2. Given the imputed complete data, D =
[
Z,C, S˜obs, I{Sobs ≤ C}, Y˜ obs, I{Yobs ≤ C},S∗(0)
]
, we then
draw for the following sub-vectors of θ in sequence, conditional on all others: pi, αS , βS , α¯Y , β¯Y , αY ,
βY , ν¯Y , γ¯Y , νY , γY , λ. We draw pi directly from its full conditional distribution, a Beta distribution
with parameters a +
∑n
i=1 I{S∗i (0) = S} and b +
∑n
i=1 I{S∗i (0) ∈ R+}. We cannot draw directly
from the appropriate conditional distributions for the other model parameters, but we use Metropolis–
Hasting steps for drawing from their full-conditional distributions. For instance, to draw αS , we draw
a candidate value αcandS from a density g(αS | θ). The candidate draw is accepted with probability
pαS = min
{
P
{
[θ \ αS ], αcandS |D
}
P {[θ \ αS ], αS |D}
g(αS | [θ \ αS ], αcandS )
g(αcandS | [θ \ αS ], αS)
, 1
}
For the candidate densities, we use Gamma densities for the parameters αS , α¯Y , αY , ν¯Y , and νY and
Normal densities for the parameters βS , β¯Y , βY , γ¯Y , γY , and λ, centered at the current values of the
parameters. The scaling factors were chosen based on preliminary runs of the chains.
Details of Calculations: κ ∈ (0, 1]
Let (θ,S∗(0),Y ∗(0)) denote the current state of the chain, with
θ =
[
pi, (αS , βS) ,
(
α¯Y , β¯Y
)
, (αY , βY ) , (ν¯Y , γ¯Y ) , (νY , γY ) , λ, κ = κ0
]
κ0 ∈ (0, 1].
1. Given the parameter θ, observed data, Dobs, and S∗(0) draw the missing data Y ∗i (0)
− For control patients, we set Y ∗i (0) = Y˜ obsi
− For treated patients, we never observe Yi(0)We use Metropolis-Hasting steps to draw Yi(0) accord-
ing to P
(
Yi(0) | θ, Si(0), Dobsi
)
. We draw candidate values Y candi (0) from Weibull distributions:
(a) For treated patients with S∗i (0) = S, we draw Y candi (0) from a Weibull distribution with
parameters
(
α¯Y , β¯Y
)
; and (b) for treated patients with S∗i (0) ∈ R+, we draw Y candi (0) from the
following location shifted Weibull distribution: S∗i (0) + Weibull (αY , βY + λ log(S
∗
i (0))).
For each i with Zi = 1, we accept Y
cand
i (0), setting Y
∗
i (0) = Y
cand
i (0), with probability pi =
12
min{pYi(0), 1}, with
pYi(0) =

ri ·
fSY (0)(Y
∗
i (0))
fSY (0)(Y
cand
i (0))
if S∗i (0) = S, I{Y obsi ≤ Ci} = 0
ri ·
fSY (0)(Y
∗
i (0))
fSY (0)(Y
cand
i (0))
if S∗i (0) = S, I{Y obsi ≤ Ci} = 1, Y candi (0) ≤ Y˜ obsi /κ
ri ·
fY (0)(Yi(0))
fY (0)(Y
cand
i (0))
if S∗i (0) ∈ R+, I{Y obsi ≤ Ci} = 0
ri ·
fY (0)(Y
∗
i (0))
fY (0)(Y
cand
i (0))
if S∗i (0) ∈ R+, I{Y obsi ≤ Ci} = 1, Y candi (0) ≤ Y˜ obsi /κ
0 if I{Y obsi ≤ Ci} = 1, Y candi (0) > Y˜ obsi /κ
where fSY (0)(·) and fY (0)(·) are the densities of the proposal Weibull distributions, and
ri =
P
{
θ | Dobsi , S∗i (0), Y candi (0)
}
P
{
θ | Dobsi , S∗i (0), Y ∗i (0)
} .
2. Given the parameter θ, observed data, Dobs, and Y ∗(0) draw the missing data S∗i (0)
− For control patients, we have
S∗i (0) = Si(0) =

S if Zi = 0, I{Sobsi ≤ Ci} = 0, I{Y obsi ≤ Ci} = 1
S˜obsi = S
obs
i if Zi = 0, I{Sobsi ≤ Ci} = 1, I{Y obsi ≤ Ci} ∈ {0, 1}.
For control patients with I{Sobsi ≤ Ci} = 0 and I{Y obsi ≤ Ci} = 0, we have
piNS ≡ P
(
S∗i (0) = S | θ, Zi = 0, Ci, S˜obsi , I{Sobsi ≤ Ci} = 0, Y˜ obsi , I{Y obsi ≤ Ci} = 0
)
=
piGSY (0)(Ci)
piGSY (0)(Ci) + (1− pi)GSi(0)(Ci) · 1
Therefore control patients with I{Sobsi ≤ Ci} = 0 and I{Y obsi ≤ Ci} = 0 are classified as
non-switchers (S∗i (0) = S) with probability piNS and as switchers with censored switching time
(S∗i (0) = S˜
obs
i = Ci) with probability 1− piNS
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− For treated patients, we never observe S∗i (0) = Si(0). We use Metropolis-Hasting steps to draw
Si(0) according to P
(
Si(0) | θ, Dobsi
)
. We draw candidate values Scandi (0) from a semi-continuous
distribution: We first draw n1 values from a Bernoulli distribution with probability pi setting
Scandi (0) = S for treated units for which we obtain a success (a positive value). For treated
units for which we obtain a failure, a missing value of Scandi (0) is then drawn from the Weibull
distribution with parameters αS and βS : Weibull (αS , βS). For each i with Zi = 1, we accept
Scandi (0), setting S
∗
i (0) = S
cand
i (0), with probability pi = min{pSi(0), 1}, with
pSi(0) =

ri if S
∗
i (0) = S, Scandi (0) = S
ri · pi
(1− pi)fS(0)(Scandi (0))
if S∗i (0) = S, Scandi (0) ∈ R+, Scandi (0) ≤ Y ∗i (0)
ri ·
(1− pi)fS(0)(S∗i (0))
pi
if S∗i (0) ∈ R+, Scandi (0) = S
ri ·
fS(0)(S
∗
i (0))
fS(0)(S
cand
i (0))
if S∗i (0) ∈ R+, Scandi (0) ∈ R+, Scandi (0) ≤ Y ∗i (0)
0 if Scandi (0) ∈ R+, Scandi (0) > Y ∗i (0)
where fS(0)(·) is the density of the proposal Weibull distribution, Weibull (αS , βS), and
ri =
P
{
θ | Dobsi , Scandi (0), Y ∗i (0)
}
P
{
θ | Dobsi , S∗i (0), Y ∗i (0)
} .
3. Given the imputed complete data, D =
[
Z,C, S˜obs, I{Sobs ≤ C}, Y˜ obs, I{Yobs ≤ C},S∗(0),Y ∗i (0)
]
,
we then draw for the following sub-vectors of θ in sequence, conditional on all others: pi, αS , βS ,
α¯Y , β¯Y , αY , βY , ν¯Y , γ¯Y , νY , γY , λ, using the procedure described in step 2. in Section “Details of
Calculations: κ = 0.”
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Table 2: Summary statistics of the posterior distributions
Percentiles
Parameter Mean sd 2.5% 25% 50% 75% 97.5% R̂
pi 0.38 0.06 0.28 0.33 0.37 0.42 0.50 1.001
αS 1.56 0.11 1.35 1.48 1.56 1.63 1.79 1.001
βS −1.29 0.15 −1.55 −1.39 −1.29 −1.19 −0.98 1.001
αY 1.38 0.13 1.14 1.29 1.38 1.47 1.67 1.000
βY −1.09 0.21 −1.49 −1.24 −1.09 −0.94 −0.68 1.000
αY 0.94 0.12 0.72 0.86 0.94 1.02 1.19 1.000
βY −1.21 0.15 −1.51 −1.31 −1.20 −1.11 −0.92 1.000
ν.y 1.29 0.11 1.09 1.22 1.29 1.36 1.51 1.000
γY −1.85 0.29 −2.43 −2.04 −1.84 −1.65 −1.30 1.000
νY 1.30 0.10 1.11 1.23 1.30 1.36 1.50 1.000
γY −2.24 0.23 −2.70 −2.39 −2.24 −2.09 −1.81 1.000
λ 0.10 0.17 −0.22 −0.02 0.09 0.21 0.44 1.000
Application: Additional Results
Convergence Checks
We use the potential scale-reduction statistic (Gelman and Rubin 1992) to assess convergence of the MCMC
algorithm: the potential scale reduction statistic takes on values around 1 for all the model parameters,
showing no evidence against convergence (see Table 2). Figure 1 shows the trace plots, which exhibit up-
and-down variation with no long-term trends or drift, showing further evidence that convergence has been
reached. Finally Figure 2 shows the posterior distributions of the model parameters which are generally well
shaped.
Distributional Causal Effects for Switchers
Figure 3 shows the posterior median of the distributional causal effects for switchers. The distributional
causal effects are almost always positive with a increasing tread over time for switchers who would switch
to zidovudine early after the assignment. For switchers who would switch to zidovudine between 0.75 and
1.25 years after the assignment, the distributional causal effects are negative for early durations greater than
the switching time, and become positive for later durations. The later the switching time, the longer the
durations are until which the distributional causal effects are negative. For instance, the distributional causal
effects for patients who would switch to zidovudine 0.75 years after the assignment are negative, ranging
between −0.03 and −0.003, for few durations longer than 0.75 years (between 0.75 and about 0.9 years). The
distributional causal effects for patients who would switch to zidovudine 1.25 years after the assignment are
negative, ranging between −0.127 and −0.0002, for durations longer than 1 year (between 1.25 and about
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Figure 1: Trace plots of the model parameters
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Figure 2: Posterior density of the model parameters
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Figure 3: Principal stratification analysis: Posterior median of the distributional causal effects for switchers,
DCE(y | s), for s = 0.25, 0.50, . . . , 2.50, 2.75
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Figure 4: Principal stratification analysis: Posterior median of the distributional causal effects DCE(y | s),
for s = 0.25, 0.50, . . . , 2.50, 2.75, for different values of κ
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2.3 years). These results are, at least partially, driven by the natural constrain Si(0) ≤ Yi(0). Therefore, we
need to interpreter distributional causal effects for patients who would switch at a given time s, bearing in
mind that these effects are defined as comparison between the probability under assignment to immediate
treatment with zidovudine that switchers at time s will survive beyond any specified time, y ≥ s, with
the probability under assignment to deferred treatment with zidovudine that those switchers will survive
beyond y ≥ s, given that they have survived beyond the time-to-switching, s. It is then sensible that some
distributional causal effects are negative, especially for long switching durations: immediate versus deferred
treatment with zidovudine should have a very strong effect for making these distributional effects positive.
Sensitivity Analysis to κ: Distributional Causal effects for Switchers
Figure 4 compares the posterior medians of DCE(y | s) for s = 0.25, 0.50, . . . , 2.50, 2.75. We vary κ in
{0, 0.25, 0.5, 0.75, 1}. Note that at κ = 1, DCE(y | s) = cDCE(y | s).
Two major patterns appear in the posterior medians of DCE(y | s). First, the posterior medians are
negative for some durations greater than the switching time both at κ = 0 and κ ∈ {0.25, 0.5, 0.75}, but the
posterior medians of at κ ∈ {0.25, 0.5, 0.75} turn to be positive at earlier durations. Second, the posterior
medians for switchers who would switch to zidovudine early after the assignment show an increasing trend
over time at κ = 0, whereas those derived at κ ∈ {0.25, 0.5, 0.75} increase over time until around 1 year and
then start to decrease.
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Figure 5: Principal stratification analysis:Posterior median of the distributional causal effects for switchers,
cDCE(y | s), for s = 0.25, 0.50, . . . , 2.50, 2.75, for different prior distributions for λ (κ = 0)
DCE(y | s)
λ ∼ N(0, 1) λ ∼ N(0, 10) λ ∼ N(0, 10 000) λ ∼ Uniform(R)
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Sensitivity Analysis to the Prior Distribution for λ: Distributional Causal effects
for Switchers
Posterior Predictive Checks
We evaluate the influence of the parametric assumptions using posterior predictive checks (e.g., Guttman
1967; Rubin 1984), by computing a Bayesian posterior predictive p-value (PPPV ) for various discrepancy
measures (Meng 1994; Gelman et al. 1996; Forastiere et al. 2018). A discrepancy measure is a known,
real-valued function of the nuisance parameters, the imputed switching status, and the observed data. The
corresponding Bayesian PPPV is defined as the integral average over the joint posterior distribution of the
missing switching statuses and model parameters of the probability that the discrepancy measure calculated
for replicated data is more extreme than the value of the discrepancy measure calculated for observed data.
Replicated data are drawn from the posterior predictive distribution of the hypothesized model. A PPPV is
a measure of model misfit, with the model including both the prior distribution and the likelihood. Extreme
values (close to 0 or 1) of a PPPV would indicate that the model is not able to adequately preserve features
of the data reflected in the discrepancy measure.
We conduct model checking under conditionally independent potential survival outcomes with κ = 0. Let
r be the study type indicator: r = obs for the observed study and r = rep for a replicated study. We generate
the replicated data using the observed value of the assignment variable, and of the entry and censoring time,
that is, setting Zrepi = Z
obs
i = Zi and C
rep
i = Ci for all i = 1, . . . , n.
We measure the goodness-of-fit of the posited model using three types of posterior predictive discrepancy
measures:
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1. BIC posterior predictive discrepancy measure.
BICr = −2 (L{θ | κ = 0,Dr}+ ]{θ \ κ} · log(n)) ,
where Dr = [Z,C, S˜
r
, I{Sr ≤ C}, Y˜ r, I{Yr ≤ C},S∗,r(0)] is the n × 7 matrix of the complete
switching status data, L{θ | κ = 0,Dr} is the complete switching status-data likelihood function for
κ = 0, and ]{θ \ κ} is the number of parameters excluding κ (]{θ \ κ} = 12 in our study).
2. Deviance posterior predictive discrepancy. The deviance, defined as the sum of the deviance
residuals for the Weibull model. We calculate the deviance posterior predictive discrepancy measure
separately for the survival time and the switching time under control for switchers. For r = obs, rep,
DeviancerY (D,θ) =
−2
∑
i:Zi=0,1
 ∑
i:Zi=z,S
∗,r
i (0)=S
[
MSY (z)(Y˜
r
i ) + I{Y ri ≤ Ci} log
(
I{Y ri ≤ Ci} −MSY (z)(Y˜ ri )
)]
+
∑
i:Zi=z,S
∗,r
i (0)∈R+
[
MY (z)(Y˜
r
i | S∗,ri (0)) + I{Y ri ≤ Ci} log
(
I{Y ri ≤ Ci} −MY (z)(Y˜ ri | S∗,ri (0))
)]
where MSY (z)(·) and MY (z)(· | Si(0)) are the martingale residuals for non-switchers and switchers,
respectively: MSY (z)(Y˜
r
i ) = I{Y ri ≤ Ci} − ΛSY (z)(Y˜ ri ) if Si(0) = S, and MY (z)(Y˜ ri | Si(0)) = I{Y ri ≤
Ci} − ΛY (z)(Y˜ ri | Si(0)) if Si(0) ∈ R+, with ΛSY (z)(·) and ΛY (z)(· | Si(0)) denoting the cumulative
hazards for the Weibull model (Therneau et al. 1990). Similarly, we define
DeviancerS(D,θ) = −2
∑
i:Zi=0,S
∗,r
i (0)∈R+
MS(0)(S˜
r
i )+I{S∗,ri (0) ≤ Ci} log
(
I{S∗,ri (0) ≤ Ci} −MS(0)(S˜ri )
)
.
3. Kaplan–Meier posterior predictive discrepancy. We calculate Kaplan–Meier estimates of the
survival curve for the time-to-death/disease progression, separately for non-switchers and switchers,
and for the time-to-switching under control for switchers.
For data from study type r, r = obs, rep, for each time-point t, let drY (t | S∗,ri (0) ∈ A) be the number
of events (deaths or disease progressions) at time t among patients with S∗,ri (0) ∈ A, A = {S} (non-
switchers) and A = R+ (switchers), and let drS(t | Zi = 0, S∗,ri (0) ∈ R+) be the number of switchers
assigned to the control treatment who switch at time t. Let RrY (t | S∗,ri (0) ∈ A) denote the number
of subjects with S∗,ri (0) ∈ A, A = {S},R+, at risk of death or disease progression at time t, and
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RrS(t | Zi = 0, S∗,ri (0) ∈ R+) denote the number of switchers assigned to the control treatment at risk
of switching at time t. We define
KMrA(t;D,θ) =
∏
i:S∗,ri (0)∈A
[
1− d
r
Y (t | S∗,ri (0) ∈ A)
RrY (t | S∗,ri (0) ∈ A)
]
A = {S},R+;
and
KMr(t;D,θ) =
∏
i:Zi=0,S
∗,r
i (0)∈R+
[
1− d
r
S(t | Zi = 0, S∗,ri (0) ∈ R+)
RrS(t | Zi = 0, S∗,ri (0) ∈ R+)
]
.
Following Barnard et al. (2003), we then consider posterior predictive discrepancy measures aimed to
assess the ability of the model to preserve features in the outcome distributions of non-switchers and switchers
that we think can be very influential in estimating the average and distributional causal effects.
Define the following subsets of units in the study of type r (r = obs, rep):
IrA,z = {i : I{Y ri ≤ Ci}I{S∗,ri (0) ∈ A}I{Zi = z} = 1}
for A = {S} and A = R+, and z = 0, 1; and
Ir = {i : I{S∗,ri (0) ≤ Ci}I{S∗,ri (0) ∈ R+}I{Zi = 0} = 1}
Let Y
r
A,z and s
2,r
Y,A,z be the mean and the variance of the survival outcome, Yi, for units belonging to
IrA,z, for which we observe Yi(z) in study r. Similarly, let S
r
and s2,rS the mean and the variance of the
switching time, S∗i (0), for units belonging to Ir, for which S∗i (0) is observed in study r. Then,
SignalrA(D,θ) =
∣∣∣Y rA,1 − Y rA,0∣∣∣ NoiserA(D,θ) =
√
s2,rY,A,0
]IrA,0
+
s2,rY,A,1
]IrA,1
RatiorA(D,θ) =
SignalrA(D,θ)
NoiserA(D,θ)
Signalr(D,θ) = S
r
Noiser(D,θ) =
√
s2,rS
]Ir Ratio
r(D,θ) =
Signalr(D,θ)
Noiser(D,θ)
where ]IrA,z =
∑n
i=1 I{i ∈ IrA,z} and ]Ir =
∑n
i=1 I{i ∈ Ir} are the number of units in the r data belonging
to the IrA,z and Ir group, respectively.
It is worth noting that these measures are not treatment effects, but they provide information on whether
the model can preserve broad features of signal, noise, and signal-to-noise ratio in the survival time distri-
butions for non-switchers and switchers and in the switching time distribution for switchers assigned to the
control arm.
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Table 3: Bayesian Posterior Predictive p−values
Variable Deviance Signal Noise Signal to noise
Survival time 0.810
Non-Switchers 0.333 0.542 0.329
Switchers 0.429 0.725 0.372
Switching time 0.478 0.398 0.336 0.568
PPPV for BIC : 0.553
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Figure 6: Bayesian posterior predictive p−values for Kaplan-Meier posterior predictive discrepancy measures
(t = 0.01, 0.02, . . . , 2.00, 3.00)
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Table 3 shows the Bayesian PPPV s. The PPPV s for the BIC and deviance posterior predictive dis-
crepancy measures range between 0.478 and 0.810 suggesting that our model fits the data pretty well. The
PPPV s for the Kaplan-Meier posterior predictive discrepancy measures are also sufficiently faraway from
zero and one for all time points t, except for very short durations, shorter than 0.06 (approximately 22 days)
for the Kaplan-Meier posterior predictive discrepancy for the time-to-switching under control for switchers
and shorter than 0.01 (approximately 4 days) for the time-to-death/disease progression for switchers. It is
worth noting in the observed data no patient assigned to the control treatment is observed to switch to the
active treatment within 22 days and no patient is observed to either die or experience a progression of the
disease within 4 days. Results provide no special evidence for specific influences of the model, too. The
estimated Bayesian PPPV s for the signal, noise and signal-to-noise ratio posterior predictive discrepancy
measures range between 0.329 and 0.568, suggesting that our model successfully replicates the corresponding
measure of location, dispersion, and their relative magnitude.
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